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INTRODUCTION 
Problem discovery 
                Antimicrobial-resistance is emerging worldwide at an alarming rate 
among Gram-negative bacteria causing both community-acquired and hospital-
acquired infections.1,2 One of the most important emerging resistance profiles in 
bacteria belonging to the Enterobacteriaceae family corresponds to resistance to 
extended-spectrum β-lactams (ESBLs).2,3,4 Extended spectrum β-lactamases are β-
lactamase enzymes that have the ability to hydrolyze penicillins, extended-spectrum 
cephalosporins (oxyimino-β-lactams), and aztreonam, but not carbapenem or 
cephamycin antibiotics. ESBLs are reported worldwide among different bacterial 
species, including Enterobacteriaceae and non-fermentative Gram-negative bacteria 
such as Pseudomonas and Acinetobacter species.72 
                      The major reservoir for such bacteria is the gastrointestinal tract.5 
Preceding gastrointestinal colonization by antimicrobial resistant bacteria has been 
associated with subsequent infection.6A study in America (USA) has emphasized 
the importance of identifying individuals carrying antimicrobial-resistant bacteria 
in both patient and healthy populations.7 Another study reported that an increase in 
the proportion of carriage of antimicrobial-resistant bacteria in the community 
increases the risk that other individuals will also become carriers via human-to-
human transmission.8,9,10 In addition, the admission into hospital of patients 
harboring resistant bacteria increases the risk of other hospitalized patients 
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contracting an infection.8,11,12 The actual prevalence of extended-spectrum β-
lactamase (ESBL) producing organisms in healthy humans in the community 
settings is largely unknown and possibly under estimated.13,14 The acquisition of 
antibiotic resistance genes at birth has been recently reported, with the mode of 
delivery affecting rates of acquisition,15,16 however most studies on the community 
carriage of antimicrobial-resistant bacteria have been cross-sectional, and targeted 
adult populations.14,17,18,21 In addition, few longitudinal birth-cohort studies 
describing the acquisition of ESBL producing organisms have been conducted 
worldwide including India.22,23  
Associated factors influencing the emerging of ESBL 
         Several risk factors have been found to be which include prolonged 
hospitalization, prolonged ICU stay, multiple hospitalization, invasive procedures, 
immunosuppression and recent antibiotic treatment.35,36,37 Other risk factors for 
ESBL rectal carriage are old age (older than 65 years), female sex and MRSA 
carriage.37 
        In the community, risk factors are still not clear but factors that enhance the 
spread of these organisms include lack of hygiene, overuse and over-the counter use 
of antibacterial drugs, and increased worldwide travel.13 
           Many studies have reported isolation of ESBL producing organisms from 
raw vegetables, fruits as well as food of animal origins. It is most likely that these 
animals might have acquired the ESBL producers from human contacts, at the same 
time, origin among themselves cannot be entirely ruled out. Although there are not 
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many reports indicting human acquisition of ESBL producers following 
consumption of contaminated animal food, the risk is always there.13  
 
 
 
Figure 1.The environmental reservoirs of antimicrobial resistance.  
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Rationale and motivation 
          Antimicrobial-resistance in Gram-negative bacteria is a public health concern 
due to the limited availability of treatment options.2,24,25 The prevalence of 
antimicrobial-resistant in Gram-negative bacteria that produce either extended-
spectrum β-lactamases (ESBLs) has been increasingly reported over the past years, 
both in hospitals and communities worldwide.3,4 The microorganisms producing 
ESBLs may be responsible for infections that are life-threatening, thus resulting in 
increased healthcare-associated costs, morbidity and mortality.26  The first line drugs 
for the treatment of severe infections caused by ESBL-producing bacteria are the 
carbapenems,27 however their efficacy is highly compromised by the emergence and 
spread of carbapenemase-producing bacteria worldwide.28,29 The strains that 
produce ESBLs often carry resistance determinants for other classes of 
antimicrobial agents, and infections caused by these strains are associated with high 
mortality.30,31,32 A major concern is the coexistence of multiple ESBL genes that has 
led to the emergence of organisms that are resistance to nearly all antibiotics.33 
 
            The prevalence of ESBL- producing organisms has been described in 
considerable detail in certain parts of the world.30,32 The emergence of ESBLs has 
different epicenters, but they are now wide spread worldwide.13 ESBLs have spread 
widely geographically, causing outbreaks in many parts of the world,32 and this is 
likely to be the case with carbapenemases.34  
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            In India also, their prevalence is increasingly reported in both hospital and 
community settings.41, 42   Therefore, this review gives an overview of the prevalence 
of ESBL producers in India. 
 
             Therefore, this study aimed for the first time in our territory teaching 
hospital, to evaluate the prevalence of ESBL producing Esch.coli and Klebsiella in 
the clinical isolates, the present status of antibiotic resistance in Esch.coli and 
Klebsiella and to compare the results of phenotyping method with molecular typing 
for the successful treatment of the patient management and to apply proper control 
measures.   
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Aim and objectives 
 
1. To evaluate the prevalence of ESBL producing Esch.coli and Klebsiella in 
the clinical isolates at Sree Mookambika Institute of Medical Sciences, 
Kulasekaram. 
2. To study the present status of antibiotic resistance in Esch.coli and 
Klebsiella. 
3. To compare the results of phenotyping method with molecular typing. 
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A review on the prevalence of extended-spectrum β-lactamase producing 
bacteria 
        The prevalence of ESBL producing organisms has been substantially described 
in Europe, North America, Asia and Africa.13,34In India also, their prevalence is 
increasingly reported in both hospital and community settings.41,42 Therefore, this 
review gives an overview of the prevalence of ESBL producers in India.  
An overview of antibiotic resistance 
Discovery and occurrence of antibiotic resistance 
                Before discovery of penicillin by the British scientist Alexander Fleming 
in the late 1920s, infectious diseases were the leading cause of mortality 
worldwide.43,44 The introduction of penicillin in the 1940s and together with 
vaccination resulted in improved life expectancy and reduced mortality rate due to 
infectious diseases during the 20th century.43,45 However, soon after its introduction, 
penicillin-resistant Staphylococcus aureus was detected.46 The resistance to 
penicillin was due to bacterial production of penicillinase, a β-lactamase enzyme 
capable of hydrolyzing penicillin.46,47 Other antibiotics such as tetracycline, 
streptomycin and chloramphenicol were introduced in the late 1940s, likewise 
resistance to these antibiotics was also noted soon after their 
introduction.48Antibiotic resistance, defined as the ability of bacteria to resist the 
effects of antibacterial drugs, is one of the world most pressing public health 
threats.48,49Infections caused by multidrug-resistant (MDR) organisms are 
increasingly reported worldwide, with very limited treatment options.1,2 Lack of 
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effective treatment of patients infected with MDR organisms has led to high 
mortality and morbidity rates.50The rate of novel antibiotic discovery is currently 
very low compared to the increasing resistance problem.51 Among other factors, 
multiple mechanisms of resistance to antibiotics makes it difficult to develop or 
discover effective antibiotics.50,51 
Mechanisms of antibiotic resistance 
               Resistance can be either an inherent trait of the bacterium or acquired.52A 
variety of bacterial species possess innate resistance through inherited 
mechanisms.53Some bacteria can mutate to highly resistant forms, however, this 
accounts for a small proportion of antimicrobial resistance.48 Most bacteria become 
resistant to antibiotics through the getting hold of resistance-conferring 
deoxyribonucleic acid (DNA) from other sources.53,54 Antimicrobial resistance 
genes can be carried on a plasmid, chromosome, or transposon; however, most of 
these genes are encoded on plasmids, which are self-replicating extra-chromosomal 
pieces of DNA in which may themselves carry transposons.53,55Transposons are 
non-self-replicating pieces of genetic material that can be easily exchanged between 
plasmid to plasmid, chromosome to chromosome, or between plasmid and 
chromosome.55Transposon also play a major role in disseminating resistance genes 
among bacterial species.53 
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Figure 2.Transposon mechanism. 
 
Resistance genes can be spread from one bacterial species to another by conjugation, 
transformation, or transduction. Plasmids can transfer genetic material through 
conjugation.55 Transduction is a process in which a bacteriophage is needed for 
exchange of genetic material; whereas, transformation is the uptake of free DNA 
from the environment.53 
 
Figure 3. Mechanism of gene exchange. 
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            Bacterial resistance to antibiotics can be caused by either the enzymatic 
modification of an antibiotic which renders it ineffective, the modification of its 
target site so that it is unable to exert its effect, active physical removal of the 
antibiotic from the cell, or by reduction of uptake into the bacterial cell due to 
changes in membrane permeability.53 The main resistance mechanism is the 
enzymatic inactivation of an antibiotic and the most clinically important example of 
this is β-lactamase enzymes, the enzymes that hydrolyze β-lactam antibiotics.56,57 
This review will focus β-lactamase enzymes, which are the subject of this study. 
 
β-lactams 
Classification of β-lactams 
 
β-lactams are a broad class of antibiotics that are widely used for treating bacterial 
infections.58 All antibiotics in this class contain, in their molecular structure, a β-
lactam ring which is a four membered lactam (figure 4). β-lactam antibiotics 
include: the penicillins, cephamycins, cephalosporins, monobactams, carbapenems 
and β-lactamase inhibitors.58 
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Figure 4. Core structure of penicillin and β-lactam ring. 
 
The β-lactam ring is the active site of the β-lactam antibiotics that irreversibly bind 
to the penicillin binding proteins (PBPs) thus blocking their action of synthesizing 
a peptidoglycan layer. This leads to the weakened bacterial cell wall; and the 
bacterium eventually bursts.59 
 
Penicillins 
         Penicillins are effective against most Gram-positive and some Gram-negative 
bacteria. Several types of penicillins exist; the natural penicillins (penicillin G), 
penicillinase resistant penicillins (e.g. methicillin and oxacillin) and amino-
penicillins (e.g. ampicillin and amoxicillin). The first two types of penicillins have 
lethal effects on many Gram positive organisms, whereas amino-penicillins are 
effective against an extensive range of bacteria including some Gram-negative 
bacteria.60,61 
Review of literature 
 
12 
 
 
Cephalosporins and cephamycins 
 
Cephalosporins are subdivided into five generations including the closely related 
cephamycin compounds and together they establish a group of β-lactams called 
cephems. The 1st generation cephalosporins (e.g. cefazolin and cephalothin) were 
active pre-dominantly against Gram-positive cocci. The 2nd generation 
cephalosporins are more active against Gram-negative bacilli and are somewhat less 
effective against Gram-positive cocci. Unlike the 1st and 2nd generation 
cephalosporins, the 3rd generation cephalosporins have increased activity against 
both Gram-negative and Gram-positive organisms. Among the 4th generation 
cephalosporins, cefepime is the most commonly used antibiotic. The 4th generation 
cephalosporins have the similar activity against Gram-positive bacteria as the 1st 
generation cephalosporins; however, they have a greater activity against 
Enterobacteriaceae and Pseudomonas aeruginosa than the 3rd generation 
cephalosporins. The 5th generation cephalosporins (ceftaroline and ceftobiprole) 
notably improved activity against Gram-positive bacteria such as methicillin-
resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus 
aureus bacterias.62,63 
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Monobactams 
 
A currently marketed monobactam is aztreonam, an antibiotic with a very good 
activity against aerobic and fastidious Gram-negative bacilli such as 
Enterobacteriaceae and Pseudomonas aeruginosa bacterias. Aztreonam has poor 
activity against anaerobes and Gram-positive organisms.64 
 
Carbapenems 
 
Carbapenems are normally mentioned to as the antibiotics of last alternative and are 
bactericidal for both Gram-negative and Gram-positive organisms. They are known 
to be the effective antibiotics against various multidrug-resistant Gram-negative 
bacilli. Carbapenems consist of imipenem, ertapenem, meropenem and 
doripenem.65 
 
β-lactamase inhibitors 
 
Clavulanic acid, tazobactam and sulbactam are β-lactamase inhibitors that inhibit a 
number of plasmid-mediated β-lactamases. They generally don’t inhibit 
chromosomally-mediated β-lactamases. The combination of β-lactamase inhibitors 
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with β-lactams significantly increases spectrum of activity against many organisms 
containing plasmid-mediated β-lactamases.66 
 
Mechanism of action and resistance 
 
                β- lactam antibiotics are bactericidal and inhibit the growth of sensitive 
bacteria by inhibiting the D-alanyl-D-alanine-transpetidases, the penicillin-binding 
proteins (PBPs) that facilitate the transpeptidation of peptidoglycan synthesis, an 
important component of the bacterial cell wall. Peptidoglycan, a murein, contains 
of amino acids and sugars that form an important part of the bacterial cell wall. β-
lactam antibiotics are analogues of D-alanyl-D-alanine, the terminal amino acid 
residues on the precursor N-acetyl muramic acid/N-acetyl glucosamine 
(NAM/NAG) peptide subunits of the peptidoglycan  layer. This structural 
resemblance allows the binding of β-lactams to the active site of PBPs. The β-lactam 
ring permanently binds to the Ser 403 residue of the PBP active site by acylation 
there by preventing the final transpeptidation or cross linking of budding 
peptidoglycan layer by the PBPs, disrupting synthesis of the bacterial cell wall 
followed by cell death. The main mechanisms of resistance to β-lactam antibiotics 
are decreased penetration of β-lactams due to the production of modified porins, 
loss of porins or a shift in the types of porins found in the outer membrane of Gram-
negative bacteria, increased efflux from the cell through production of efflux pumps, 
or inactivation of β-lactams by chromosome- and /or plasmid-encoded β-lactamase 
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enzymes (Figure 5). Among the above-mentioned, the most common mechanism of 
resistance is the production of β-lactamases.67,68 
 
Figure 5.mechanisms of β-lactam resistance in Gram-negative bacilli. 
 
 
 
β-lactamases 
 
 
          Increased use of β-lactam antibiotics has been associated with the emergence 
of β-lactamase-mediated bacterial resistance. β-lactamases are enzymes that 
inactivate β-lactam antibiotics by cleaving the β-lactam ring through an irreversible 
hydroxylation of an amide bond (Figure 6).Two classification schemes for β-
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lactamases are currently in use, the functional (Bush-Jacoby group) and molecular 
classification (Ambler classification).Functional classification aligns β-lactamases 
based on their ability to hydrolyze specific β-lactams classes and on the inactivation 
properties of β–lactamase inhibitors. The widely used molecular classification 
(Ambler classification) is based on the amino acid sequences and divides the β-
lactamases into four classes. Class A, C, and D enzymes require serine at their active 
sites for substrate hydrolysis, whereas class B metallo β-lactamases utilize divalent 
zinc ion for substrate hydrolysis. The production of β-lactamases may be inducible 
or constitutive. In Gram-positive bacteria, β-lactamases are generally inducible, 
resulting in larger amounts of enzymes produced in the presence of an antibiotic. In 
Gram-negative bacteria, the production of β-lactamases is frequently constitutive, 
i.e. the enzyme is produced even when the antibiotic is not present. However, 
ampicillin class C β-lactamases (AmpCs) are inducible in certain Gram-negative 
bacteria, such as Escherichia, Enterobacter,  Serratia and Citrobacter species.70,71 
Transmissible plasmids have acquired genes for AmpC enzymes, which 
subsequently can now appear in bacteria deficient or poorly expressing a 
chromosomal AmpC gene, such as Escherichia coli, Klebsiella pneumoniae and 
Proteus mirabilis.119 
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Figure 6. Diagram showing the mechanism of action of β-lactamases. 
 
                β-lactamase enzyme causes an opening in the β-lactam ring represented 
an active penicillin ineffective (inactive penicillin). After the introduction of 
penicillin, resistance to this antibiotic emerged in Staphylococcus aureus due to a 
plasmid mediated penicillinase that specifically hydrolyzed penicillin.46,47 
Penicillinase spread quickly to other species of staphylococci. Resistance to 
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penicillin led to the development of many new β-lactams; however, with each new 
class of β-lactams developed, new β-lactamases active against that class of 
antibiotics emerged. Some of these new classes of antibiotics were the 3rd and 4th 
generation cephalosporins and carbapenems which became the most common 
agents for treating infections caused by Gram-negative bacilli.13,32,33 However, the 
rapid emergence of resistance to β-lactams due to AmpCs and extended-spectrum 
β-lactamases (ESBLs)is of a great public health alarm.13,34 AmpCs are β–lactamases 
that hydrolyze broad and extended-spectrum cephalosporins, but are not inhibited 
by β-lactamase inhibitors.  
 
Evolution of β-lactamases 
Since the discovery of plasmid (R factor) mediated antibiotic resistance in the1940s, 
the scientific community has observed different strategies embraced by the bacteria 
to acquire and distribute antibiotic resistance. The bla-SHV type ESBLs have 
initiated from the chromosomal bla-SHV of K. pneumoniae. The fact that first bla 
gene in Klebsiella spp was found on a transposon suggests that this mobile genetic 
element has played a role in the escape of genes from the chromosome into the 
plasmid85. The origin of bla-TEM enzymes is less certain, but they are almost 
always found encoded on plasmids with exceptions of bla-TEM-12 and bla-TEM-
134, whose genes were found on chromosomes 86. The origin of bla-CTX-M genes 
have drawn to the  chromosomal bla genes of Klebsiella spp. Phylogenetic studies 
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suggest that bla-CTX-M genes of bla-CTX-M-1 cluster has evolved from 
chromosomal bla genes of K.cryocrescens, bla-CTX-M-2 cluster from K. ascorbata 
whereas CTX-M-8, CTX-M-9 andCTX-M-25 clusters have evolved from K 
georgiana 90. Mobile genetic elements such as transposon (Tn1, Tn2, Tn3, Tn21), 
integrons (Class 1, 2), insertion sequences (ISEcp1, IS26, ISCR1) and even 
bacteriophages are believed to have helped these genes cross the genus barrier 88. 
While mutations are the primary reason for the large numbers of allelic variants, 
recombination events too have played a role 90. 
 
Figure 7: Evolution of β-lactamases 
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Extended spectrum β -lactamase-producing bacteria 
 
Extended spectrum β-lactamases are β-lactamase enzymes that have the ability to 
hydrolyze penicillins, extended-spectrum cephalosporins (oxyimino-β-lactams), 
and aztreonam, but not carbapenem or cephamycin antibiotics. ESBLs are reported 
worldwide among different bacterial species, including Enterobacteriaceae and non-
fermentative Gram-negative bacteria such as Pseudomonas and Acinetobacter 
species.72 
 
Class A extended-spectrum β –lactamases 
 
bla-CTX-M (cefotaximase, Munich), bla-SHV (sulfhydryl variable) and bla-TEM 
(Temoneira) types are the most clinically common Ambler class A ESBL enzymes, 
and susceptible to β-lactamase inhibitors (Table 1).72 The first plasmid-encoded 
ESBL enzymes were identified among Enterobacteriaceae in the 1980s; they were 
derived mainly from the narrow spectrum enzymes (bla-TEM-1, bla-TEM-2, or bla-
SHV-1) by point mutations resulting in amino acid changes conferring an extended-
spectrum of activity against β-lactams. Unlike bla-SHV and bla-TEM enzymes, bla-
CTX-M enzymes had independent evolution. Although ESBLs were first reported 
as plasmid-encoded, they are not completely plasmid-encoded; recent studies have 
shown that ESBL genes are also carried on chromosomes.69 
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bla-CTX-M type ESBLs 
 
bla-CTX-M enzymes were derived from the chromosomal cephalosporinase of 
Kluyvera species, and the first bla-CTX-M enzyme was discovered in an E. coli 
clinical isolate from Munich, Germany in 1989.It was suggested that bla-CTX-M 
genes was apprehended by mobile elements from the chromosomes of Kluyvera 
species. bla- CTX-M enzymes are classified into five groups; bla-CTX-M-1, -2, -8, 
-9 and 25. Enzymes within the same bla-CTX-M group share about 94% similarity, 
however ≤90% similarity is noticed between members of different groups. bla-
CTX-M enzymes have greater hydrolytic activity against cefotaxime than other 
oxyimino-β-lactams, hence the name bla-CTX-M (cefotaximase, Munich). 
However, some bla-CTX-M enzymes have greater activity against ceftazidime. bla-
CTX-M-15, -16, -19, -25, -27, and -32 have higher hydrolytic activity against 
ceftazidime due to point mutations around their active sites.74 In addition, bla-CTX-
M enzymes exhibit higher significant hydrolytic activities against cefepime than 
detected with other ESBL types. All bla-CTX-M enzymes have ESBL phenotype, 
and are commonly identified among Enterobacteriaceae, mainly Esch. coli and K. 
pneumoniae.73 
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bla- TEM type ESBLs 
The first bla-TEM enzyme (bla-TEM-1) was discovered in 1965 in Athens (Greece) 
from a patient infected with Esch. coli, named Temoneira, hence the name bla-
TEM. bla- TEM-1 is the  common plasmid-mediated β-lactamase causing 
ampicillin resistance among Enterobacteriaceae; responsible for up to 90% of 
ampicillin resistance in Esch. coli. Both bla-TEM-1 and bla-TEM-2 have hydrolytic 
activity against ampicillin and early-generation cephalosporins. All bla-TEM-type 
ESBLs were derived from bla-TEM-1 and bla-TEM-2.bla-TEM-type ESBLs 
hydrolyze ceftazidime with higher efficiency than other oxyimino β-lactams. Some 
bla-TEM-type ESBL variants possess silent substitutions without amino acid 
changes (bla-TEM-1a and bla-TEM-1b) and others have single amino acid changes 
enough to assign a new number (bla-TEM-3, -4, -5, etc.). Up to date, about 84 bla-
TEM variants have an ESBL phenotype. These are commonly identified in 
Enterobacteriaceae.69 
 
bla-SHV type ESBLs 
 
bla-SHV type ESBLs are derived from narrow-spectrum bla-SHV-1 or bla-SHV-
11 β-lactamases as a result of point mutations. Initially, bla-SHV-1 was described 
as plasmid-encoded and later as chromosomally encoded among K. pneumoniae 
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isolates. bla-SHV-1 or bla-SHV-11 is responsible for ampicillin resistance and 
accounts for up to 80% to 90% of resistance in K. pneumoniae. bla-SHV type 
ESBLs have greater hydrolytic activity against ceftazidime than other oxyimino-β-
lactams (cefotaxime, cefepime). bla-SHV type ESBLs are mainly found in 
Enterobacteriaceae and P. aeruginosa and the most common are bla-SHV-2a, -5 
and -12.75 
 
Class D extended-spectrum β–lactamases 
 
bla-OXA type ESBLs are the only Ambler class D ESBL enzymes. bla-OXA type 
ESBLs are less common and were named bla-OXA for their greater activity against 
oxacillin or cloxacillin and extended-spectrum β-lactams. bla-OXA type ESBLs 
primarily hydrolyze ceftazidime and are poorly inhibited by clavulanic acid. About 
16 bla-OXA type ESBL enzymes have been discovered; especially in Pseudomonas 
aeruginosa and Esch. coli strains.69 
 
Global prevalence of ESBL-producing bacteria 
Prevalence of ESBL-producers 
 
          Enterobacteriaceae are the main bacterial species associated with the 
production of ESBLs.38 Enterobacteriaceae are commonly found in human 
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gastrointestinal tract (GIT). However, these organisms can cause a variety of extra-
intestinal infections in the lower and upper urinary tracts, bloodstreams, central 
nervous system, pelvis or abdomen and wounds. The most important 
Enterobacteriaceae species associated with ESBL production are Esch. coli and K. 
pneumoniae.39 ESBL-producing Enterobacteriaceae (ESBL-PE) often display 
resistance to multiple drugs and co-resistance to other antibiotics used for treatment 
(aminoglycosides, fluoroquinolones and trimethoprim) is common. Treatment 
options for severely ill patients are limited, resulting in increasing morbidity and 
mortality rates. ESBL- producing Enterobacteriaceae species are therefore a 
growing public health worry worldwide. The prevalence and distribution of ESBLs 
varies widely in different geographical regions, differs from country to country, as 
well as within the country between hospital and community settings.38,39 
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Table 1. Classification schemes for bacterial β-lactamases, modified from Bush 
and Jacoby 2010. 
Ambler 
Class 
Bush 
group 
Representative 
examples 
Gene location Substrate 
preference 
Inhibited 
by 
 
 
 
 
 
 
 
 
A 
2a,2b 
 
TEM-1/2 
SHV variants 
Plasmid, Plasmid / 
chromosome 
Penicillin 
 
Clavulanate, 
sulbactam 
 
2be 
 
ESBL (TEM-3- 
TEM-100, CTX-M) 
SHV-3-SHV-54 
Plasmid 
Transposon 
Plasmid/chromosome 
Ampicillin, 2nd 
and 3rdgeneration 
cephalosporins 
Clavulanate, 
tazobactam 
2br 
 
TEM (IRTs) 
SHV IRTs 
 
Plasmid, Plasmid / 
chromosome 
 Ampicillin, 
Cephalosporins 
Tazobactam 
2c 
 
Carbenicillin 
Hydrolyzing 
 
 
Carbenicillin  
2e 
 
Cephalosporinase  Cephalosporins Clavulanate 
,Tazobactam 
2f 
 
NMC-A, IMI, 
SME-1 to SME-3 
 
Chromosome 
 
 
Ampicillin, 
aztreonam, 
carbapenems 
Clavulanate 
,Tazobactam 
2f 
 
KPC-1 to KPC-3, 
GES-1 to GES-2 
 
Plasmid 
Plasmid-integron 
 
Ampicillin, 
cephalosporins, 
aztreonam, 
carbapenems 
Clavulanate 
, 
Tazobactam 
 
B 
3a,3b,3c Zinc metallo β – 
lactamases IMP-
1 to IMP-14, 
VIM-1 to VIM-3 
Some 
chromosome, often 
plasmid and 
integrin 
Cephalosporins, 
cephamycins, 
penicillins 
EDTA 
 
C 
1 AmpC-type 
CMY, MOX, 
FOX, ACT-1 
DHA-2 
Originally only 
chromosome, now 
plasmids 
Cephalosporins, 
cephamycins, 
penicillins 
Cloxacillin 
 
 
 
D 
2d 
 
 
OXAs, PSEs, 
OXA-23-27, 40, 
48 
 
Chromosome, 
plasmids some on 
integrons  
Oxacillin, 
Penicillin, 
carbenicillin, 
cephaloridine 
plus 
carbapenems  
Clavulanate 
4 Miscellaneous 
AVS-1 
   
EDTA: Ethylene diamine tetra acetic acid 
 
The Bush and Jacoby group or functional classification takes into account the 
substrate and inhibitor profiles whereas the Ambler or molecular classification is by 
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protein sequence, whereby the beta-lactamases are classified into four molecular 
classes (A,B, C and D) based on conserved and distinguishing amino acids 
motifs.(CA, clavulanic acid; TZB, tazobactam; EDTA, ethylene diamine tetra acetic 
acid) 
Prevalence of ESBL-producing bacteria in Europe 
In Europe, the prevalence of ESBL- producing Enterobacteriaceae varies between 
countries.40The prevalence is low in Scandinavian countries but is rapidly 
increasing. A surveillance study conducted in South Western Sweden during 2004 
to 2008 reported a greater increase in the prevalence of bla-CTX-M-producing 
Esch. coli isolates in hospitals (0.2% - 2.5%) than in the community (0.2% – 1.6%). 
In contrast, the prevalence of ESBL- producing Enterobacteriaceae is high in the 
Southern and Eastern parts of Europe.40 Spain study shoes 7 (6.7%) of 105 healthy 
humans were carriers of ESBL-producing Esch. coli, and bla-CTX-M-14 was the 
most dominantenzyme.76 A study conducted in Portugal, the faecal carriage of 
ESBL-producing Esch. coli in patients with UTI caused by these microorganisms 
was 68%(36/53), but the domestic members and the non-domestic relatives of these 
patients also had ESBL-producing Esch. coli in faecal samples, 27.4% (20/73) and 
15.6% (5/32),respectively, whilst in healthy unrelated controls the faecal carriage 
rate was 7.4%(4/54).77In Germany, ESBL-producers were recovered from animals, 
including dogs, cats and horse, and the authors also described an active transmission 
of such organisms between humans and animals.78 
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Prevalence of ESBLs in America 
In America, data on ESBL- producing Enterobacteriaceae organisms both in 
hospital and community settings are scarce. As well, a recent survey from the USA 
including 26 hospitals from 20 states reported the prevalence of 6.4% (195/3049) of 
ESBL-producers among Enterobacteriaceae isolates.79 
Prevalence of ESBLs in Africa 
In Madagascar, ESBL- producing Enterobacteriaceae carriage was described in 
10.1% of 484 patients of all ages (median age, 28 years) attending a health care 
setting for the first time. As in other studies, bla-CTX-M-15 was frequently 
identified, 86.8% of ESBL- producing Enterobacteriaceae isolates, mainly in Esch. 
coli and K. pneumoniae isolates. Other ESBL- producing Enterobacteriaceae 
isolates identified bla-SHV-12-producing Ent. cloacae, bla-CTX-M-3-producing 
Esch. coli, bla-CTX-M-1-producing Esch.coli and bla-SHV-2a-producing K. 
pneumoniae. In the latter study, the occupational status of the head of domestic and 
shortage were risk factors for ESBL- producing Enterobacteriaceae carriage.20 
 
Prevalence of ESBLs in Asia 
 
                 A cross sectional study conducted in rural community of Thailand 
reported a very high ESBL- producing Enterobacteriaceae faecal carriage of 58.2% 
in 160 healthy adult individuals (mean age; 56.0 ± 9.8 years).80InChina, among 270 
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healthy adults, the faecal carriage rate of ESBL-producing Esch. coli was7%. Unlike 
in most parts of the world where bla-CTX-M-15 is predominant, in South-East Asia 
the most common ESBL enzyme is bla-CTX-M 14.81 
 
Prevalence of ESBL producers in India 
 
The data was collected from international surveillance studies, which included 
multiple centers from India. As a part of the MYSTIC Surveillance program, 
bacterial samples were collected from six cities (New Delhi, Lucknow, Indore, 
Mumbai, Bangalore and Vellore) across India prior to 2000. The prevalence of 
ESBL producers in that study was very high; 92% of Esch. coli and 96% of K. 
pneumonia were found to be ESBL producers.91 Interestingly, another publication 
of the same study reported ESBL production in >61% and >55% among Esch. coli 
and Klebsiella spp, respectively.92India is included in the Asia-Pacific SMART 
study in 2007 and samples collected from nine centers in that period showed 
prevalence of ESBLs in 79% of Esch.coli and 69.4% of K. pneumoniae isolates 93. 
In one of the centers included in that study, a prevalence rate of 94.1% was detected 
among Esch. coli isolates. ESBL producers were found responsible for 78.9% of 
both nosocomial and community acquired infections in that study. In the 2008 Asia-
Pacific SMART study, samples collected from seven centers across India described 
a prevalence of ESBLs in 61.2% of Esch. coli and 46.8% K.pneumoniae isolates.94 
The prevalence rates increased marginally in the subsequent study. The 2009 Asia-
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Pacific SMART study, reported a prevalence rate of 67.1%among Esch. coli and 
56.8% among K. pneumoniae isolates.95 
                       In the same period, multinational Asian Network for Surveillance of 
Resistant Pathogens (ANSORP) surveillance study reported similar prevalence 
(57.1%) of ESBL-Klebsiella from Indian centers.96 
The regional Resistance Surveillance (RRS) program in the Asia-Pacific (APAC) 
region reported a slightly increased prevalence of ESBLs; 78% of Esch. coli and 
64% of K. pneumoniae isolates were found to be ESBL producers.97Although there 
are numerous studies from various parts of India, they differ widely in patient 
population, sample type and size, detection methodology and the study period. 
Hence, even with a vast amount of data, meaningful interpretation is difficult to 
achieve.  
               In the period 2013-14, the rates of ESBL detection among Esch. coli 
ranged from24-90% and that of K. pneumoniae ranged from 9-80% in the Northern 
parts of India.98 
              In the Eastern parts, the rates ranged from 12-89% among Esch. coli and 
26-93% among K. pneumoniae isolates.100 
               In the central parts of India, the rates ranged from 41-50% among Esch. 
coli and 26-48% among K. pneumoniae isolates.101 
                 In the western India, the rates ranged from 20-62% among Esch. coli and 
15-67%among K. pneumoniae isolates.117 
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In the southern India, the rates ranged from18-73% among Esch. coli and 33-63% 
among K. pneumoniae isolates.102 
 
ESBL types in India 
 
 The first report of an ESBL producer from India came in 1998, when bla-
SHV-5 ESBL was discovered among Salmonella isolated from patients 
during an outbreak in a burns ward at Delhi.103 
 In 2001, Karim et al reported detection of 70 bla-CTX-M-15 in clinical 
isolates of Esch. coli, K. pneumoniae, and Ent. aerogenes collected in 1999 
in a hospital at Delhi.112 This is the first account of a bla-CTX-M enzyme 
that was also capable of hydrolyzing ceftazidime. 
 In 2006, Ensor et al reported detection of bla-CTX-M-15 in 73% of Esch. 
coli and K.pneumoniae isolates collected from centers located in Aligarh, 
Varanasi and Hubli.104 
 In response to this publication, Walsh et al reported that their study team, 
which had collected samples from New Delhi, Mumbai, Indore, Lucknow, 
Bangalore and Vellore prior to 2000, had identified bla-CTX-M- 15 in 83% 
of Esch. coli and 75% of Klebsiella sps.91 
 bla-CTX-M -15 still continues to be the dominant bla-CTX-M type in India. 
Several studies from India have detected bla-CTX-M genes among the 
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clinical isolates by amplifying only a part of the bla-CTX-M gene. Many of 
these studies had used multiplex PCR protocols, which allow the researchers 
to detect only the bla-CTX-M groups but not their individual members. 
 In 2008, a study from Chennai reported detection of bla-CTX-M-1 ESBL 
among Enterobacteriaceae members.105 Authors of that study, used the same 
primer pairs for another study and reported detection of bla-CTX-M-28,bla-
CTX-M-1, bla-CTX-M-15 and bla-CTX-M-28 belong to the bla-CTX-M-1 
cluster; bla-CTX-M-15 differs from bla-CTX-M-1 by four amino acids but 
bla-CTX-M-28 differs from bla-CTX-M-15 by one amino acid at 
position289. The primers used by the authors of those two studies are more 
suitable for detecting bla-CTX-M-15 ESBLs than bla-CTX-M-1 or bla-
CTX-M-28. The possibility of miss identification of bla-CTX-M-28 by using 
primers designed for bla-CTX-M-15 pointed out by Menezes et al.106 
 In 2009, a report from Chennai detected bla-SHV-28 in a clinical isolate of 
K.pneumoniae and claimed it to be an ESBL since the isolate gave positive 
ESBL phenotypic test and is electric focusing revealed only a single band 
.As now, bla-SHV-28 is not established an ESBL. Among the few reports on 
bla-SHV type ESBLs, bla-SHV-12, followed by bla-SHV-2, bla-SHV-4 and 
bla-SHV-5 are the only ones reported from India.99 
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Detection methods for ESBL- and carbapenemase-producers 
Detection of extended-spectrum β -lactamases 
 
Extended-spectrum β -lactamases can be detected with phenotypic or genotypic 
approaches. 
 
Phenotypic tests 
 
The phenotypic detection of ESBLs includes screening and confirmatory steps. 
Screening involves testing for reduced susceptibility to extended spectrum β-
lactams, including cefotaxime, ceftazidime, cefpodoxime, ceftriaxone or aztreonam. 
Cefpodoxime is the most sensitive indicator for detecting ESBLs, because it can be 
hydrolyzed by all common bla-CTX-M, bla-SHV, and bla-TEM ESBLs. But, it is 
less specific than the combination of cefotaxime (or ceftriaxone) and ceftazidime. 
Confirmatory phenotypic tests are based on the demonstration of synergy between 
the Extended spectrum β-lactams and β-lactamase inhibitors particularly clavulanic 
acid. Several confirmatory tests including combination disc test, double-disc 
diffusion test, ESBL E-test or ESBL NDP test are used in different settings. In 
addition, auto mated systems (the Vitek ESBL and BD Phoenix ESBL tests) that 
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use the above mentioned detection principle are in use in many clinical 
microbiology laboratories.82,83 
 
Combination disc test (CDT) 
 
  Principle: 
The CDT detects the production of ESBL enzymes based on that they hydrolyze 
cephalosporin antibiotics and are inhibited by clavulanic acid (Figure8).  
Test: 
Ceftazidim and Cefotaxime or Ceftriaxone alone and in combination with 
clavulanic acid is preferred in isolates with inducible AmpC enzymes as this 
antibiotic is stable to AmpC β-lactamases.84 AmpC enzymes interfere with 
clavulanic acid synergy and detecting ESBL production in such isolates using 
cefotaxime or ceftazidime is challenging. 
Advantage: 
The test is cheap and easy to perform, and interpretation is straight forward.  
Sensitivity and specificity: 
The sensitivity and specificity of this test using cefotaxime and ceftazidime alone 
and in combination with clavulanic acid have been reported to be 96% and 100%, 
respectively; however, the sensitivity of this test can be further increased by using 
cefepime alone and in combination with clavulanic acid.84  
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Figure 8. Combination disc test (CDT) showing an increase by at least 5mm for 
cefotaxime-clavulanic acid, ceftazidime-clavulanic acid and cefepime-clavulanic 
acid as compared to cefotaxime, ceftazidime and cefepime, respectively. CPM, 
Cefepime; CPM+CV, Cefepime-clavulanic acid; CAZ, Ceftazidime; CAZ+CV, 
Ceftazidime-clavulanic acid; CTX, cefotaxime; CTX+CV, Cefotaxime-clavulanic 
acid. 
 
Double-disc Diffusion test (DDT) 
 The DDT was the first test designed to detect ESBL production in 
Enterobacteriaceae. 
 The cephalosporin discs are applied to a plate next to a disc containing 
clavulanate (amoxicillin-clavulanate). 
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 A positive result is indicated when the zone of inhibition around any of the 
cephalosporin discs is augmented in the direction of the disc containing 
clavulanate. 
 This method has remained a reliable test for the detection of ESBLs in 
clinical microbiology laboratories. 
 In addition, the DDT is also cheap and easy to perform; however, reading the 
results is some time difficult.83 
 
ESBL E-tests 
 
 The ESBL E-tests contain the gradients of cephalosporin alone at one end of 
the strip and combined with 4 μg/ml of clavulanic acid on the other end.  
 The ESBL E-test is considered positive when the minimum inhibitory 
concentration (MIC) of the cephalosporin combined with clavulanic acid is 
reduced by ≥8-fold as compared with the MIC of the cephalosporin alone or 
if a deformed ellipse or phantom zone is present. 
 The ESBL E-test is easy to perform but the interpretation of results is 
sometimes challenging.  
 In 2002, a study conducted in The Netherlands reported failure of laboratory 
technicians to recognize the phantom zones or ellipse deformation in 30% of 
cases.83 
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ESBL Nordmann Dortet Poirel (ESBL NDP) test 
 
       This is a newly established phenotypic test for the detection of ESBLs in 
Enterobacteriaceae. The ESBL NDP test detects the production of ESBL based on 
the hydrolysis of cefotaxime. A red phenol solution is used as a pH indicator, and 
when a protein extract from the bacterium is mixed with red phenol solution 
containing cefotaxime, ESBLs contained within the protein extract hydrolyze the 
antibiotic, thus forming an acidic solution which causes the pH indicator to turn 
from red to yellow or orange. In the presence of tazobactam the activity of ESBLs 
will be inhibited, and the pH indicator will remain red (unchanged color), thus 
confirming the production of the ESBL (Figure 7).47 Its sensitivity and specificity 
in detecting bla-CTX-M-type and bla-SHV-12 enzymes have been reported to be 
98.0% and 99.8%, respectively.47 Only few studies have evaluated this test.47 
 
Figure 9. The ESBL NDP test showing the hydrolysis of cefotaxime in bla-CTX-
M-15-producing K. pneumonia isolate (tube B). The action of ESBL enzyme (bla-
CTX-M-15) is inhibited in the presence of tazobactam (tube C). There is no 
hydrolysis of cefotaxime in case of ESBL negative Esch. coli (tube B).  
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Genotypic tests 
 Polymerase chain reaction (PCR) and subsequent sequencing of ESBL genes 
or DNA microarray-based methods are used for genotypic confirmation of 
the presence of specific ESBL genes. 39 
  Singleplex or multiplex PCR techniques may be used. Molecular tests 
remain the gold standard and are technically challenging, however, they have 
the advantage of identifying the specific type of ESBL gene present in a 
bacterium.2 
 These techniques can detect low-levels of resistance, and can be performed 
without prior culture of the microbiological specimens.2  
 The PCR tests are rapid and the results are usually obtained within six hours 
with excellent sensitivity and specificity. The main disadvantages of 
molecular techniques are their cost and inability to detect unidentified novel 
ESBL genes. 
Conclusion: 
The data on the prevalence of ESBL-producing bacteria in Indian setting continue 
inadequate. There are also few studies on the prevalence of ESBL-producers in 
healthy individuals in the community. In addition, only few studies describing the 
acquisition of ESBL- producing bacteria at birth have been conducted worldwide. 
Consequently, we sought to study the epidemiology of ESBL-producing bacteria in 
a birth cohort among apparently healthy South Indian, to describe community 
acquired ESBL producers and anti- microbial resistance.   
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Material and Methods 
 Study design 
Non randomized cross sectional study. 
Place of study 
Department of Microbiology Sree Mookambika Institute of Medical Sciences, 
Kulasekharam. 
Period of study 
The study was carried out from July 2015 to June 2016. 
 Study population 
All clinical isolates of Esch.coli and Klebsiella, from urine, pus, blood, vaginal 
swab, ear swab, fluid aspirates(plural, acidic)and wound swab from the OPD and 
ward of Gynecology, Surgery, Medicine, Orthopedics, ENT,ICU and  Nephrology 
departments. 
Sample size 
One hundred bacterial isolates. 
Data collection 
 By excel sheet. 
Sampling technique 
Convenient sampling.   
Data analysis 
Descriptive analysis, Data entered in to Microsoft excel. 
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I. Significant level decided before starting of study: P= <0.05 
II. Statistical tests to be used for data analysis: chi square test 
III. Software(s) to be used for Statistical analysis: SPSS trail version 20.0 
 
 Sample size determination 
 
N = 4pq/d2 
 
n= Desired sample size, 
p= Prevalence of the disease / problem   
      in community (50%) 
q= (1-p), 
d= Degree of accuracy (10%), 
4= Confidence interval (95%) 
 
 
N= 4x50x50/(10)2 
   = 4x50x50/10x10 
   = 4x50x50/100 
   = 100 
 
Prevalence rate 50%. 
Table 2. Sample size determination 
 
 
Collection of samples 
 Collection of urine sample 
            A sterile, dry, wide mouth container and request for 10-20 ml specimen. 
Clean catch, mid-stream urine. The female patients were advised to clean the area 
around the urethral opening with clean water, dry the area and collect the urine with 
the labia a part .The male patients were advised to wash the hands before collecting 
the specimen.89 
Collection of skin wound, ear, fluids ect. 
           A sterile technique was applied to aspirate or collect pus or wound swab from 
abscess or wound infection, either by disposable syringe or by sterile swab stick. 
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Specimen was collected in a sterile container with cap, before an antiseptic dressing 
is applied. Special care was taken to avoid contamination with commensal 
organisms from the skin.89  
Collection of blood  
                Blood was collected under strict aseptic precaution 5ml disposable 
syringe and immediately inoculated into BHIB and transfer to the microbiology lab 
and kept in to the incubator.89 
Screening of ESBL-producing Esch.coli and Klebsiella 
Inoculation of samples 
All samples received for culture and sensitivity from various departments in Sree 
Mookambika Institute of Medical Science like urine, sputum, pus and blood, ect are 
processed. The urine samples were inoculated in CLED and BA, blood was 
inoculated in to BHIB and pus, sputum, swabs fluids and tips were inoculated in to 
BA and MA. These entire samples were processed immediately after receiving. 
Blood samples were sub cultured after overnight inoculation and on 5th day in to the 
MA and BA for isolation. In between bottles are examined daily and sub-cultured 
into solid media if there is any visible sign of growth. After 24 hours period the 
plates were observed, the colony and organism was identified by biochemical test – 
Gram staining, motility, Oxidase, Catalase, mannitol motility, triple sugar iron, 
indole, citrate, and urease.109  
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Figure 10: Culture identification  
Isolation and identification of organisms 
Grams staining 
From the MA plate gram stain obtained to isolate Gram negative bacilli. 
 
Figure 11: Gram stain microscope view  
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GRAM-
POSITIVE 
 GRAM-
NEGATIVE 
 
 
Fixation 
 
   
 
 
Crystal Violet 
 
   
 
 
Iodine Treatment 
 
   
 
 
Decolorisation 
 
   
 
 
Counter stain with 
Safranin  
 
Figure 12: Procedure of Gram Staining89 
Oxidase test: 
This test was used to identify the organisms, which produce the enzyme oxidase.89  
  
Figure 13: PC-Positive control, T-Test, NC-Negative control 
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Motility test: 
Hanging drop used to test the motility of the bacteria. Here Esch.coli was motile 
and Klebsiella was non-motile.89  
 
Figure 14: Manitol Motility test 
Catalase test: 
Tube catalase test used to identify the Enterobacteriaceae family. This study 
Esch.coli and Klebsiella were catalase positive.89  
  
Figure 15: Catalase test (PC – Positive control, NC – Negative control, T - Test) 
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Citrate utilization test: 
Simons citrate agar media was used for differentiating the intestinal bacteria and 
other micro organisms on the basis of citrate utilization. This study Esch.coli was 
not utilized citrate and Klebsiella utilized citrate.89  
 
  
Figure 16: Citrate utilization test (PC-Positive control, T-Test, NC-Negative 
control) 
 
 Indole production test: 
Indole production was tested for some bacteria, which has the ability to reduce 
tryptophan to indole. Indole production was detected by Kovacs reagent. Esch.coli 
and Klebsiella oxytoca are Indole positive and Klebsiella pneumonia are indole 
negative.89   
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Figure 17: Indole production test. (PC-Positive control, T-Test, NC-Negative 
control) 
Triple sugar iron agar (TSI): 
This media was used for initial identification of Gram negative bacilli, particularly 
members of Enterobacteriaceae. The three primary characteristics of a bacteria to 
be include in the ability to ferment carbohydrate (lactose, sucrose, glucose,), ability 
to produce gas, and the production of hydrogen sulfide gas. Esch.coli and Klebsiella 
fermented all the three carbohydrates and produced gas without H2S.89  
  
Figure 18: K/A H2S- Alkaline/Acid with hydrogen sulfide gas, A/A-Acid/Acid, A/A 
–Acid/Acid with Gas, K/A-Alkaline/Acid, NC-Negative control, T-Test (Acid/Acid 
with Gas). 
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Manitol motility test: 
Semisolid media used to see the motility and manital fermentation. Esch.coli and 
Klebsiella fermented manitol were else Klebsiella was non moile and Esch.coli was 
motile.89 
  
Figure 19: Manitol motility test (PC-Positive control, T-Test, NC-Negative control) 
Urea hydrolysis test: 
             Christensen’s urea medium used to hydrolysis of urea to produce ammonia 
and alkalinize the media. Esch.coli is not hydrolysing and Klebsiella was 
hydrolyzing urea.89 
  
Figure 20: Urea hydrolysis test.      (PC-Positive control, T-Test, NC-Negative control) 
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Properties used to characterize Esch. coli K. pneumoniae and K.oxytoca are 
shown below: 
 
 
 
Properties Esch. coli K. pneumoniae K.oxytoca 
Gram stain Gram negative 
bacilli 
Gram negative 
bacilli 
Gram negative 
bacilli 
Motility Motile Non-motile Non-motile 
Catalase test Positive Positive Positive 
Oxidase test Negative  Negative Negative 
Indole test Positive Negative Positive 
TSI A/A G+ H2S- A/A G+ H2S- A/A G+ H2S- 
MMannital motility 
test 
M+M+ M+M- M+M- 
Citrate utilization 
test 
Negative Positive Positive 
Ureas test Negative Positive Positive 
 
 
Table 3:  characters of  Esch. coli K. pneumoniae and K.oxytoca 
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Flowchart 1: Methodology of study 
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Maintenance of culture strains 
Organisms grown in appropriate media for 18 hours were preserved in a nutrient 
agar slant at 2-80 C in a refrigerator and this culture were sub cultured every 2 weeks 
and maintained till the end of this study. These cultures were used for all the 
tests.108,112 
Antimicrobial susceptibility  
Kirby-Bauer sensitivity testing method was used for antibiotic sensitivity. From the 
nutrient agar slant pure cultures of bacteria was grown overnight on MacConkey 
agar, a suspension matching 0.5 McFarland standard (1.5 x 108CFU/ml) was made 
in nutrient broth. Using sterile cotton swab, the bacteria were spread on Mueller 
Hinton agar to obtain a lawn culture. After allowing the plate to dry, the above 
mentioned disks were placed on the surface and the plates were incubated in air at 
37oC for 18-24 hours. The diameters of the zone of inhibition around the disks were 
measured and recorded Antimicrobial discs used for Gram negative bacteria were 
Ampicillin 10 µg(AMP), Cephotaxime 30 µg(CTX/CF), Ceftriaxone 30 µg(RP), 
Ceftazidime 30µg(FG), Gentamicin 10 µg(GM), Amikacin 30 µg(AK), 
Ciprofloxacin 5 µg(RC), Imipenem 10 µg(IM), Cefoxitin 30µg(CK), Cefepime30 
µg(ZX).107,109,111 
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Susceptibility breakpoints of antibiotics tested by disk diffusion method 
 
Antibiotics           Zone diameter 
 Strength S (mm) IM (mm) R (mm) 
Cefoxitin  (CK) 30µg ≥18 15-17 ≤ 14 
Ceftazidime (FG) 30µg ≥21 18-20 ≤ 17 
Cefotaxime (CTX/CF) 30µg ≥26 23-25 ≤ 22 
Ceftriaxone (RP) 30µg ≥23 20-22 ≤ 19 
Cefepime (ZX) 30µg ≥18 15-17 ≤ 14 
Ampicillin (AMP) 10 µg ≥17 14-16 ≤ 13 
Gentamicin (GM) 5 µg ≥15 13-14 ≤ 12 
Amikacin (AK) 30µg ≥17 15-16 ≤ 14 
Ciprofloxacin (RC) 5 µg ≥21 16-20 ≤ 15 
Imipenum (IM) 10 µg ≥23 20-22 ≤ 19 
                                              S-sensitive, IM- Intermediate, R-Resistant     
Table 4:   Antibiotics tested by disk diffusion method 
 
Screening test for ESBLs 
         Resistance to cefotaxime, ceftazidime, ceftriaxone and aztreonam was 
detected by disk diffusion test as recommended by CLSI. From the pure cultures of 
bacteria grown overnight on MacConkey agar, a suspension matching 0.5 
McFarland standard (1.5 x 108 CFU/ml) was made in nutrient broth. Using sterile 
cotton swab, the bacteria were spread on Mueller Hinton agar to obtain a lawn 
culture. After allowing the plate to dry, the antibiotic disks were placed on the 
surface and the plates were incubated at 37oC for 18-24 hours. Following growth, 
the diameter of the zone of inhibition around the disks were measured and recorded. 
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The disk potency and inhibition zone diameters used for inferring resistance is 
displayed below. Resistance to at least one of the antibiotics was considered as 
positive in the screening test for possible ESBL production as per 2010 CLSI 
guidelines.44,83,116 
 
Zone diameters for inferring resistance in the screening test 
 
Antibiotic disk Resistant, if zone diameter is 
cefotaxime (30 μg) ≤ 27 mm 
ceftriaxone (30 μg) ≤ 25 mm 
ceftazidime (30 μg) ≤ 22 mm 
Table 5: Resistance in the screening test 
Confirmatory test for ESBLs 
Double disk diffusion method (DDDT) 
 
Figure 21: Double disk diffusion method (DDDT) 
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      Isolates of Esch. coli and Klebsiella that were considered to be positive for 
ESBL production by the screening test were subjected to the Phenotypic 
Confirmatory Test (CLSI-PCT) as recommended by 2010 CLSI guidelines.118From 
the pure cultures of bacteria grown overnight on MacConkey agar, a suspension 
matching 0.5McFarland standard (1.5 x 108 CFU/ml) was made in nutrient broth. 
Using sterile cotton swab, the bacteria were spread on Mueller Hinton agar to obtain 
a lawn culture. After allowing the plate to dry, disks of ceftazidime (30 μg) (FG), 
ceftazidime + clavulanicacid (30/10 μg) (CA), cefotaxime (30 μg) (CTX), 
cefotaxime + clavulanic acid (30/10μg) (CEC) were placed on the surface and the 
plates were incubated in air at 37oCfor 18-24 hours. Following growth, the diameter 
of the zones around the disks were measured and recorded. An increase in the zone 
diameter by ≥5 mm around the disks containing cephalosporin with clavulanic over 
the disks containing cephalosporin alone indicated ESBL production.112,116,118  
 
Controls:  
Esch. coli ATCC 25922 and K. pneumoniae ATCC 700603 were used as controls. 
Detection of ESBL genes from bacterial isolates 
Material: 
PureFast® Bacterial DNA minispin purification kit [Kit contains Lysozyme, 
Lysozym edigestion buffer, Proteinase-K, Binding buffer, Wash Buffer-1, Wash 
Buffer-2, Spin columns with collection tube and elution buffer. HELINI 2X ReDdye 
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PCR Master Mix, Agarose gel electrophoresis consumables and SHV, TEM and 
CTX Primers are from HELINI Bio-molecules, Chennai, India. 
2X Master Mix: 
        It contains 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
MgCl2, 1μl of 10mM dNTPs mix and RedDye PCR additives. 
Agarose gel electrophoresis: 
      Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide are 
from HELINI Bio-molecules, Chennai. 
 
 
 
PCR: 
 HELINI Ready to use SHV gene Primer mix - 5μl/reaction 
PCR Product: 276bp 
 HELINI Ready to use TEM gene Primer mix - 5μl/reaction 
PCR Product: 250bp 
 HELINI Ready to use CTX gene Primer mix - 5μl/reaction 
PCR Product: 296bp 
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Bacterial DNA Purification 
 
1ml of overnight culture 
 centrifuged at 6000rpm for 5min 
Supernatant discarded 
 Pellet is suspended in 0.2ml PBS 
Added 180μl of Lysozyme digestion buffer and 20μl of Lysozyme [10mg/ml] 
 Incubated at 37C for 15min 
Added 400μl of Binding buffer, 5μl of internal control template and 20μl of Proteinase K and 
Mixed well by inverting several times. 
 Incubate at 56ºC for 15min 
Added 300μl of Ethanol and mixed well. 
  
Transferred entire sample into the PureFast® spin column. 
 Centrifuged for 1 min 
Discard the flow-through and place the column back into the same collection tube. 
  
Added 500μl Wash buffer-1 to the PureFast® spin column. 
 Centrifuge for 30-60 seconds 
Discard the flow-through. 
 Place the column back into the same collection 
tube. 
Added 500μl Wash buffer-2 to the PureFast® spin column. 
 Centrifuge for 30-60 seconds 
Discard the flow-through 
  
Place the column back into the same collection tube. 
  
Discard the flow-through 
 centrifuge for an additional 1 min. 
(This step is essential to avoid residual ethanol) 
  
Transferred the PureFast® spin column into a fresh 1.5 ml micro-centrifuge tube. 
  
Added 100μl of Elution Buffer to the center of PureFast® spin column membrane. 
  
Incubate for 1 min at room temperature 
 centrifuge for 2 min 
Discard the column and store the purified DNA at -20°C 
 
Flowchart 2: Bacterial DNA Purification 
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Quality and Quantity of extracted DNA is checked by loading in 1% agarose gel 
and 5μl of extracted DNA is used for PCR amplification. 
PCR Procedure: 
 
 Reactions set up as follows; 
 
Components Quantity 
HELINI RedDye PCR Master mix 
 
10μl 
HELINI Ready to use – Primer Mix 5μl 
 
Purified Bacterial DNA 5μl 
 
Total volume 20μl 
Table 6: PCR Procedure 
 
 Mixed gently and spin down briefly. 
 Place into PCR machine and program it as follows; 
 Initial De-naturation: 95ºC for 5 min  
 De-naturation: 94ºC for 30sec 
 Annealing: 58ºC for 30sec                    35 cycles 
 Extension: 72ºC for 30sec 
 Final extension: 72º C for 5 min 
Loading: 
1. Prepared 2% agarose gel. [2gm of agarose in 100ml of 1X TAE buffer] 
2. Run electrophoresis at 50V till the dye reaches three fourth distances and 
observe the bands in UV Transilluminator. 
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Agarose gel electrophoresis: 
1. Prepared 2% agarose. (2gm agarose in 100ml of 1X TAE buffer and melted 
using micro oven) 
2. When the agarose gel temperature was around 60ºC, added 5μl of Ethidium 
bromide. 
3. Poured warm agarose solution slowly into the gel platform. 
4. Kept the gel set undisturbed till the agarose solidifies. 
5. Poured 1XTAE buffer into submarine gel tank. 
6. Carefully placed the gel platform into tank. Maintained the tank buffer level 
0.5cm above than the gel. 
7. PCR Samples are loaded after mixed with gel loading dye along with 10μl 
HELINI 100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 500bp, 600bp, 
700bp, 800bp, 900bp, 1000bp and 1500bp] 
8. Run electrophoresis at 50V till the dye reaches three fourth distance of the 
gel. 
9. Gel viewed in UV Transilluminator and observed the bands pattern. 
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Agarose gel electrophoresis bands pattern  
 
 
Figure 22: Agarose gel electrophoresis bands pattern 
 
 
 
 
  
 
Results 
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RESULTS 
Clinical samples 
 During the one year period from the total number of gram negative bacilli 
isolates first 50 isolates of Esch.coli and 50 isolates of Klebsiella were 
cultured from various clinical samples.  
 All the samples were collected under strict aseptic precaution to avoid cross 
contaminations. 
 All the samples were cultured soon after reaching the laboratory. 
  The urine samples were inoculated in CLED and BA, blood was inoculated 
in to BHIB and pus, sputum, swabs fluids and tips were inoculated in to BA 
and MA. 
  Blood samples were sub cultured after overnight inoculation and on 5th day 
in to the MA and BA for isolation. In between bottles are examined daily and 
sub-cultured into solid media if there is any visible sign of growth. The plates 
were incubated at 37⁰c for 24 hours.  
 After 24 hours period the plates were observed, the colony and organism was 
confirmed by gram stain and biochemical tests. 
 The distribution of the various samples and its percentage from them is 
displayed in the Table. Urine 65 (65%), Sputum 11 (11%), Stool 9(9%) and 
pus 8 (8%) were the common samples submitted for culture.  
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Table 7: Distribution of sample from various specimens 
 
Clinical sample  
 
Total number of samples 
n=100 
Percentage (%) 
 
Urine 65 65% 
Sputum 11 11% 
Stool 9 9% 
Pus 8 8% 
Blood 1 1% 
Suction tip 1 1% 
ET tip 1 1% 
Vaginal swab 1 1% 
Ear swab 1 1% 
Ascitic fluid 1 1% 
Pleural fluid 1 1% 
 
 
Figure 23: Distribution of sample from various specimens 
 
Among 100 clinical isolates 65 (65%) samples were from Urine followed by 11 
(11%) from sputum, 9 (9%) from Stool, 8 (8%) from pus. Others from blood, suction 
tip, ET tip, vaginal swab, ascitic fluid, ear swab and pleural fluid were 1 (1%) each. 
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Table 8: Detection rate of Esch.coli from the various samples  
 
Clinical sample  
 
Esch.coli n=(50) Percentage (%) 
Urine 39 78% 
Sputum 2 4% 
Pus 3 6% 
Stool 5 10% 
Blood 0 0% 
Suction tip 0 0% 
ET tip 0 0% 
Vaginal swab 0 0% 
Ear swab 0 0% 
Ascitic fluid 1 2% 
Pleural fluid 0 0% 
 
 
Figure 24: Detection rate of Esch.coli from the various samples 
 
            Among 50 isolates of Esch.coli 39(78%) samples were obtained from urine 
followed by 5 (10%) from stool, 3 (6%) from pus, 2 (4%) from sputum and 1 (2%) 
from ascitic fluid. 
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Table 9: Detection rate of Klebsiella from the various samples  
 
Clinical sample  
 
Klebsiella n=(50) Percentage (%) 
Urine 26 52% 
Sputum 9 18% 
Pus 5 10% 
Stool 4 8% 
Blood 1 2% 
Suction tip 1 2% 
ET tip 1 2% 
Vaginal swab 1 2% 
Ear swab 1 2% 
Ascitic fluid 0 0% 
Pleural fluid 1 2% 
 
 
Figure 25 : Detection rate of Klebsiella from the various samples 
 
       Among 50 isolates of Klebsiella isolates 26 (52%) were obtained from Urine, 
9(18%) from sputum, 5 (10%) pus, 4(8%) stool. 1 (2%) from others like blood, 
suction tip, ET tip, vaginal swab, ear swab and pleural fluid. 
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Anti-Biogram 
Table 10: Antibiotic susceptibility of Esch.coli  
 
 
Antibiotics 
Esch.coli(50) 
Sensitive Intermediate  Resistant 
Cefoxitin 30µg (CK) 15 (30%) - 35 (70%) 
Ceftazidim30µg (FG) 15 (30%) - 35 (70%) 
Cefotaxim 30 µg 
(CTX/CF) 
15 (30%) - 35 (70%) 
Ceftriaxone30µg (RP) 15 (30%) - 35 (70%) 
Cefepime30 µg(ZX) 21 (42%) 3 (6%) 26 (52%) 
Ampicillin10 µg(AMP) 22 (44%) - 28 (56%) 
Gentamicin5 µg(GM) 28 (56%) 4 (8%) 18 (36%) 
Amikacin30 µg(AK) 44 (88%)  6 (12%) 
Ciprofloxacin5 µg(RC) 15 (30%)  35 (70%) 
Imipenum10 µg(IM) 36 (72%) 6 (12%) 8 (16%) 
 
 
 
Figure 26: Antibiotic susceptibility of Esch.coli 
               Above table and figure shows antibiotic sensitivity and resistant pattern 
among the 50 Esch.coli isolates. 
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 Among 50 isolates of Esch.coli 30 (70%) show resistance to cefoxitin (CK), 
30 (70%) to ceftazidime (FG), 30 (70%) to ceftriaxone (RP), 30 (70%) to  
cefotaxime (CTX/CF), 30 (70%) to Ciprofloxacin (RC), 6 (12%) to  
Amikacin(AK), 28 (56%) to Ampicillin(AMP), 26 (52%) to Cefepime (ZX),  
18 (36%) to Gentamicin (GM) and 8 (16%) to Imipenem (IM). 
 In this study 30 (70%) of Esch.coli show high resistance to cefoxitin (CK), 
ceftazidime (FG), ceftriaxone (RP), cefotaxime (CTX/CF) and Ciprofloxacin 
(RC).  
 Within this 50 Esch.coli 44 (88%) show high sensitivity to Amikacin (AK) 
and 36 (72%) to Imipenum (IM).  
 Among this 40-50% show sensitivity to Cefepime (ZX), Gentamicin (GM), 
Ampicillin (AMP). 
 3 (6%) of Esch.coli show intermediate sensitivity to Cefepime (ZX), 4 (8%) 
to Gentamicin (GM) and 6 (12%) to Imipenum (IM). 
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Table 11: Antibiotic susceptibility of Klebsiella 
 
Antibiotics 
Klebsiella (50) 
Sensitive Intermediate Resistant 
Cefoxitin 30µg (CK) 27 (54%) - 23 (46%) 
Ceftazidim30µg (FG) 27 (54%) - 23 (46%) 
Cefotaxim 30 µg 
(CTX/CF) 
27 (54%) - 23 (46%) 
Ceftriaxone30µg (RP) 27 (54%) - 23 (46%) 
Cefepime30 µg(ZX) 37 (74%) 3 (6%) 10 (20%) 
Ampicillin10 µg(AMP) 35 (70%) - 15 (30%) 
Gentamicin5 µg(GM) 17 (34%) - 33 (66%) 
Amikacin30 µg(AK) 40 (80%) - 10 (20%) 
Ciprofloxacin5 µg(RC) 27 (54%) - 23 (46%) 
Imipenum10 µg(IM) 41 (82%) 2 (4%) 7 (14%) 
 
 
Figure 27:  Antibiotic susceptibility of Klebsiella 
 Among 50 isolates of Klebsiella 23 (46%) were show resistance to cefoxitin 
(CK), 23 (46%) to ceftazidime (FG), 23 (46%) to ceftriaxone (RP), 23 
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(46%) to cefotaxime (CTX/CF), 23 (46%) Ciprofloxacin (RC), 33(66%)  
Gentamicin (GM), 7 (14%) to Imipenum (IM), 10 (20%) Cefepime (ZX), 
10 (20%) to Amikacin (AK) and 15 (30%) to Ampicillin (AMP).  
 In this study 33(66%) Gentamicin (GM) shows high resistance followed by 
23 (46%) to cefoxitin (CK), ceftazidime (FG), ceftriaxone (RP), cefotaxime 
(CTX/CF), Ciprofloxacin (RC). 
 In this study 41 (82%) of klesiella show high sensitivity to Imipenum (IM) 
and 40 (80%) to Amikacin (AK).  
 Among this 70-75% show sensitivity to Cefepime (ZX) and Ampicillin 
(AMP). 
 3 (6%) Klesiella show intermediate sensitivity to Cefepime (ZX) and 2 (4%) 
to Imipenum (IM). 
 
 
Table 12: Screening test for ESBL production with 3rd Generation 
cephalosporins 
 
 Ceftazidim30µg 
(FG) 
Cefotaxim 30 µg 
(CTX/CF) 
Ceftriaxone30µg 
(RP) 
S R S R S R 
Esch.coli (50) 15 
(30%) 
35 
(70%) 
15 
(30%) 
35 
(70%) 
 
15 
(30%) 
35 
(70%) 
Klebsiella  (50) 27 
(54%) 
23 
(46%) 
27 
(54%) 
23 
(46%) 
 
27 
(54%) 
23 
(46%) 
Total (100) 42 
(42%) 
58 
(58%) 
42 
(42%) 
58 
(58%) 
42 
(42%) 
58 
(58%) 
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Figure 28: Screening test for ESBL production with 3rd Generation cephalosporins 
Screening test for ESBL production 
 Screening test involved detection of resistance to one or more of the 
3rdGeneration cephalosporin antibiotics (ceftazidime, cefotaxime, 
ceftriaxone).  
 Among 100 isolates 58(58%) isolates were found to be resistant to all the 
three 3rd Generation cephalosporins. 
 Among the 50 Esch.coli isolates, 35(70%) were found to be resistant to all 
the three screening agents. 
 In the total 50Klebsiella isolates, 23 (46%) were found to be resistant to all 
the three screening agents. Among these 2(8.7%) were K.oxytoca and were 
as 21 (91.3%) were K.pneumonia. 
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Table 13: Confirmation of ESBL production by combination Disk diffusion 
test: 
 
 CAZ/CAZC CTX/CTXC 
Name of organism Sensitive Resistant Sensitive Resistant 
Esch. coli n= 50 15 (30%) 35 (70%) 15 (30%) 35 (70%) 
Klebsiella sppn= 50 27 (54%) 23 (46%) 27 (54%) 23 (46%) 
Total n = 100 42 (42%) 58 (58%) 42 (42%) 58 (58%) 
 
 
Figure 29: Confirmation of ESBL production by combination Disk diffusion test: 
Confirmation of ESBL production by combination Disk diffusion test: 
 All the 58 isolates that were positive in the ESL screening test, were positive 
in the confirmative test by combination disk diffusion test also.  
 Among 50 Esch.coli 35(70%) isolates were positive in the screening test, and 
all of them 35 (70%) were phenotypically confirmed as ESBL producers. 
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 Similarly, from the 50Klebsiella isolates, 23(46%) were identified as ESBL 
producers and all the 23 (46%) isolates were confirmed as ESBL 
phenotypically. Among 23 Klebsiella isolates 2 (8.7%) were K.oxytoca and 
21 (91.3%) were K.pneumoniae. 
Table 14: Antibiotic resistance pattern among ESBL producers 
 Esch.coli Klebsiella 
 S IM R S IM R 
CK 0 
(0%) 
0 
(0%) 
35 
(100%) 
0 
(0%) 
0 
(0%) 
23 
(100%) 
ZX 6 
(17.14%) 
3 
(8.57%) 
26 
(74.2%) 
10 
(43.47%) 
3 
(13.04%) 
10 
(43.47%) 
AMP 15 
(42.85%) 
0 
(0%) 
20 
(57.14%) 
15 
(65.21%) 
0 
(0%) 
8 
(34.78%) 
GM 15 
(42.85%) 
3 
(8.57%) 
17 
(48.57%) 
11 
(47.82%) 
0 
(0%) 
12 
(52.17%) 
AK 30 
(85.71%) 
0 
(0%) 
5 
(14.28%) 
18 
(78.26%) 
0 
(0%) 
5 
(21.73%) 
RC 0 
(0%) 
0 
(0%) 
35 
(100%) 
0 
(0%) 
0 
(0%) 
23 
(100%) 
IMP 21 
(60.00%) 
6 
(17.14%) 
8 
(22.85%) 
14 
(60.86%) 
2 
(8.69%) 
7 
(30.43%) 
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                Above table shows antibiotic sensitivity and resistant pattern among the 
ESBL producing Esch.coli (35) and Klebsiella isolates (23) to identify the co-
resistance antibiotics.  
 
Figure 30:  Antibiotic resistance pattern among ESBL producers – Esch.coli 
 
 
Figure 31: Antibiotic resistance pattern among ESBL producers – Klebsiella 
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Antibiotic resistance pattern among ESBL producers:  
 Among 35 ESBL Esch.coli isolates all the 35 (100%) were resistance to 
cefoxitin (CK), 35 (100%) to Ciprofloxacin (RC), 5 (14.28%) to Amikacin 
(AK), 20 (57.14%) to Ampicillin (AMP), 26 (74.2%) to Cefepime (ZX), 17 
(48.57%) to Gentamicin (GM) and 8 (22.85%) to Imipenum (IM).  
 In this study ESBL all 35 (100%) Esch.coli isolates show resistance to 
cefoxitin (CK) and Ciprofloxacin (RC). 
 Among the 35 ESBL isolates 85.71% show high sensitivity to Amikacin 
(AK) and 60% to Imipenum (IM). 
 In this study ESBL isolates show 45% - 60% sensitivity to Ampicillin 
(AMP) and Gentamicin (GM).  
 Among ESBL isolates3 (8.57%) show intermediate sensitivity to Cefepime 
(ZX), 3 (8.57%) Gentamicin (GM) and 6 (17.14%) to Imipenum (IM).  
 Among 23 ESBL Klebsiella isolates 23 (100%) show resistance to cefoxitin 
(CK), 23(100%) to Ciprofloxacin (RC), 5 (21.73%) to Amikacin (AK), 8 
(34.78%) to Ampicillin (AMP), 10 (43.47%) to Cefepime (ZX), 12 (52.17%) 
Gentamicin (GM) and 7 (30.43%) Imipenum (IM).  
 In this study all the 23 (100%) show resistance to cefoxitin (CK) and 
Ciprofloxacin (RC) followed by 52.17% Gentamicin (GM).  
 Among this 78.2% show high sensitivity to Amikacin(AK), 65.21% 
Ampicillin(AMP) and 60.86% to Imipenum (IM).  
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 In this 40% - 50% of ESBL Klebsiella show sensitivity to Cefepime (ZX) 
and Gentamicin (GM).  
 3 (13.04%) ESBL isolate show intermediate sensitivity to Cefepime (ZX) 
and 2 (8.69%) Imipenum (IM).  
 
Table 15: Pattern of distribution of TEM, SHV and CTX-M genes among 
phenotypic confirmed ESBL producers 
 
 TEM SHV CTX-M 
Esch.coli (35) 26 (74.28%) 21 (60.00%) 29 (82.85%) 
Klebsiella (23) 15 (65.21%) 12 (52.17%) 19 (82.60%) 
Total (58) 39 (67.24%) 32 (55.17%) 47 (81.03%) 
 
 
 
 
Figure 32: Distribution of Genes 
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 bla-
TEM+bla-
SHV 
bla-
SHV+bla-
CTX 
bla-
TEM+bla-
CTX 
bla-
TEM+bla-
SHV+bla-
CTX 
Ech.coli 12 (34.28%) 15(42.85%) 20(57.1%) 6(17.1%) 
Klebsiella  4(17.39%) 8(34.78%) 11(47.82%) 0 (0%) 
Table 16: Pattern of distribution of bla-TEM, bla-SHV and bla-CTX-M genes 
among phenotypic confirmed ESBL producers 
  
Figure 33: Pattern of distribution of Genes with Esch.coli and Klebsiella 
 
Pattern of distribution of bla-TEM, bla-SHV and bla-CTX-M genes among 
phenotypic confirmed ESBL producers 
  
 An attempt to detect one or more bla genes by PCR in (58) all the 
phenotypically confirmed ESBL producers.  
 This included 35(60.3%) isolates of Esch. coli and 23 (39.7%) isolates of 
Klebsiella.  
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 Among 58 ESBL producers bla-TEM gene was detected in 39 (67.2%), bla-
SHV gene in 32 (55.17%) and bla-CTX-M gene in 47(81.03%) were 
detected.   
 Among 35 ESBL Esch.coli isolates, 26 (74.28%) were positive for bla-TEM 
gene, 21 (60%) were bla-SHV gene and 29(82.85%) were bla-CTX-M gene. 
 All the isolates were shows combined genes bla-TEM+bla-SHV 12(34.3%), 
bla-SHV+bla-CTX-M 15(42.8%), bla-TEM+bla-CTX-M 20(57.1%) and 
bal-TEM+bla-SHV+bla-CTX-M 6(17.1%).  
 In all the ESBL producing Esch.coli isolates more than one gene was 
detected. 
 Among 23 ESBL Klebsiella isolates included 15(65.21%) were bla-TEM, 
12(52.17%) were bla-SHV and 19 (82.60%) were bla-CTX-M. All the 
isolates were shows complaint genes bla-TEM+bla-SHV 4(17.39%), bla-
SHV+bla-CTX-M 8 (34.78%), and bla-TEM+bla-CTX-M 11 (47.82%). 
 In all the ESBL producing Klesiella isolatates more than one gene was 
detected. 
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Table 17: Relationship between Antibiotic resistance patterns with bla genes of 
Esch.coli 
A
n
ti
b
io
ti
cs
 
TEM+SHV 
(12) 
TEM+CTX-M 
(20) 
SHV+CTX-M 
(15) 
TEM+SVH 
+CTX-M (6) 
S IM R S IM R S IM R S I
M 
R 
CK 0 
0% 
0 
0% 
12 
100% 
0 
0% 
0 
0% 
20 
100
% 
0 
0% 
0 
0% 
15 
100% 
0 
0% 
0 
0
% 
6 
100% 
ZX 3 
25% 
1 
8.33% 
8 
66.66
% 
4 
20
% 
1 
5% 
15 
75% 
1 
6.66% 
1 
6.66
% 
13 
86.66
% 
1 
16.66
% 
0 
0
% 
5 
83.33
% 
AM
P 
4 
33.33
% 
0 
0% 
8 
66.66
% 
8 
40
% 
0 
0% 
12 
60% 
7 
46.66
% 
0 
0% 
8 
53.33
% 
4 
66.66
% 
0 
0
% 
2 
33.33
% 
GM 5 
41.66
% 
1 
8.33% 
6 
50% 
9 
45
% 
2 
10
% 
9 
45% 
9 
60% 
0 
0% 
6 
40% 
4 
66.66
% 
0 
0
% 
2 
33.33
% 
AK 10 
83.33
% 
0 
0% 
2 
16.66
% 
18 
90
% 
0 
0% 
2 
10% 
14 
93.33
% 
0 
0% 
1 
6.66% 
6 
100% 
0 
0
% 
0 
0% 
RC 0 
0% 
0 
0% 
12 
100% 
0 
0% 
0 
0% 
20 
100
% 
0 
0% 
0 
0% 
15 
100% 
0 
0% 
0 
0
% 
6 
100% 
IM 8 
66.66
% 
2 
16.66
% 
2 
16.66
% 
12 
60
% 
3 
15
% 
5 
25% 
11 
73.33
% 
1 
6.66
% 
3 
20% 
58.33
% 
0 
0
% 
1 
16.66
% 
CK- Cefoxitin , ZX- Cefepime, AMP-Ampicillin, GM- Gentamicin, AK- 
Amikacin, RC- Ciprofloxacin, IM- Imipenem . ( S- Sensitive, IM- Intermediate, 
R-Resistant. ) 
 Above table shows the relationship between Antibiotic resistance patterns 
with bla genes (bla TEM, bla SHV, bla CTX-M) of ESBL producing 
Esch.coli in our study. 
  In this study all combination of genes show 100% resistance to cefoxitin 
(CK) and ciprofloxacin (RC).  
  Isolates show 80% - 100% sensitivity Amikacin (AK).  
 Among this 60% - 70% show sensitive to Imipenum (IM). 
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 Among ESBL producing gens 70% - 80% were shows high resistance to 
Cefipime (ZX). 
Figure 34 : Relationship between Antibiotic resistance patterns with bla genes 
of Esch.coli
CK- Cefoxitin , ZX- Cefepime, AMP-Ampicillin, GM- Gentamicin, AK- Amikacin, RC- Ciprofloxacin, IM- Imipenum. 
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Table 18 : Relationship between Antibiotic resistance patterns with bla genes 
of Klebsiella: 
A
n
ti
b
io
ti
cs
 TEM+SHV 
(4) 
TEM+CTX-M 
(8) 
SHV+CTX-M 
(11) 
TEM+SVH+ 
CTX-M (0) 
S IM R S IM R S IM R S IM R 
CK 0 
0% 
0 
0% 
4 
100
% 
0 
0% 
0 
0% 
8 
100
% 
0 
0% 
0 
0% 
11 
100% 
0 
0% 
0 
0% 
0 
0% 
ZX 1 
25% 
1 
25% 
2 
50% 
3 
37.5
% 
0 
0% 
5 
62.5
% 
6 
54.5
4% 
2 
18.1
8% 
3 
27.27% 
0 
0% 
0 
0% 
0 
0% 
AM
P 
2 
50% 
0 
0% 
2 
50% 
4 
50% 
0 
0% 
4 
50% 
10 
90.9
0% 
0 
0% 
1 
9.09% 
0 
0% 
0 
0% 
0 
0% 
GM 2 
50% 
0 
0% 
2 
50% 
5 
62.5
% 
0 
0% 
3 
37.5
% 
4 
36.3
6% 
0 
0% 
7 
63.63% 
0 
0% 
0 
0% 
0 
0% 
AK 3 
75% 
0 
0% 
1 
25% 
5 
62.5
% 
0 
0% 
3 
37.5
% 
10 
90.9
0% 
0 
0% 
1 
9.09% 
0 
0% 
0 
0% 
0 
0% 
RC 0 
0% 
0 
0% 
4 
100
% 
0 
0% 
0 
0% 
8 
100
% 
0 
0% 
0 
0% 
11 
100% 
0 
0% 
0 
0% 
0 
0% 
IM 3 
75% 
1 
25% 
0 
0% 
4 
50% 
0 
0% 
4 
50% 
7 
63.6
3% 
1 
9.09
% 
3 
27.27% 
0 
0% 
0 
0% 
0 
0% 
 
CK- Cefoxitin , ZX- Cefepime, AMP-Ampicillin, GM- Gentamicin, AK- 
Amikacin, RC- Ciprofloxacin, IM- Imipenum. 
   S-Sensitive, IM- Intermediate, R- Resistant. 
 Above table shows the relationship between Antibiotic resistance patterns 
with bla (bla TEM, bla SHV, bla CTX-M) genes of ESBL producing 
Klebsiella in our study. 
  In this study all combination of genes shows 100% resistance to cefoxitin 
(CK) and ciprofloxacin (RC).  
 Among this 60% - 90% show sensitivity to Amikacin (AK).  
 In this 60% - 80% genes show sensitive to Imipenum (IM).  
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 Among the  ESBL producing gens 50% - 60% were shows high resistance to 
Cefipime (ZX). 
Figure 35 : Relationship between Antibiotic resistance with bla genes of Klebsiella 
CK- Cefoxitin , ZX- Cefepime, AMP-Ampicillin, GM- Gentamicin, AK- Amikacin, RC- Ciprofloxacin, IM- Imipenum.
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Discussion 
 Nowadays antibiotics 3rd Gen. Cephalosporin antibiotics are continuously 
being added for the treatment of various infections.  
 An extensive use of β-lactam antibiotics in hospital and community has 
created a major problem leading to increased morbidity, mortality and health 
care costs.  
 Proper use of antibiotics is very important to prevent multi drug resistance. 
 Prevalence of bacterial resistance against 3rd Gen. Cephalosporin antibiotics 
makes the main focus of this study. 
 In the present study, a total of 100 isolates (50 Esch.coli and 50 Klebsiella) 
were isolated from various clinical specimens.  
 Majority of the organisms were isolated from urine 65% (65/100) followed 
by Sputum 11% (11/100), Stool 9% (9/100) (Table:7) 
 Among 100 clinical isolates 65 (65%) samples were from Urine followed by 
11 (11%) from sputum, 9 (9%) from Stool, 8 (8%) from pus. Others from 
blood, suction tip, ET tip, vaginal swab, ascitic fluid, ear swab and pleural 
fluid were 1 (1%) each. 
 Among 50 isolates of Klebsiella isolates 26 (52%) were obtained from Urine, 
9(18%) from sputum, 5 (10%) pus, 4(8%) stool. 1 (2%) from others like 
blood, suction tip, ET tip, vaginal swab, ear swab and pleural fluid 
 The percentage of isolations from various clinical samples correlates with 
finding done Shiju MP et al (201o), Vipul M Khakhkhar et al (2012), 
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Archana Sharma et al (2012), Sridhar PN Rao et al (2014) and Raymond G 
Batchoun et al (2009).108,110,113,114,115  
 Among Klebsiella isolates the above studies also mention Sputum is the 
second common isolate which is correlate with present study. 
 The organism encoding multiple antibiotic resistance genes are becoming 
increasingly prevalent. In this study Esch.coli presented with (70%) high 
resistance to Cefoxitin, 3rd Gen.Cephalosporins (70%) to Ceftazidime, (70%) 
to Cefotaxim and (70%) to ceftriaxone and (70%) to Ciprofloxacin followed 
by (56%) to Ampicillin, (50%) Cefepim and (46%) Gentamicin.  
 Among this (88%) isolates show high sensitivity to Amikacin and (83%) 
Imipenum.  
 Klebsiella show (66%) high resistance to Gentamicin followed by 2nd Gen. 
Cephalosorin (46%) to cefoxitin, 3rd Gen. Cephalosporins(46%) to  
Ceftazidime, (46%) to Cefotaxim, (46%) to ceftriaxone), 46% to 
Ciprofloxacin and (30%) to Ampicillin. 
 Among this (80%) show high sensitivity to Amikacin and (86%) to 
Imipenem. 
 This present study Esch.coli shows high resistance to Cephalosporins (70%) 
and Ciprofloxacin (70%) whereas Klebsiella shows high resistance to 
Gentamicin (66%).This result correlate with Archana sharma et al 2012 and 
Shiju MP et al 2010. 114,115 
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 Vipul M Khakhkhar et al 2012 concluded that almost all ESBL producers 
resistant to ampicillin, but in the present study 42.85% ESBL producing 
Esch.coli show sensitive to Ampicillin and 65.21% ESBL producing 
Klebsiella.113 
 In the present study ESBL producing bacteria shows high sensitivity to 
Amikacin and Imipenem, which  correlates with Shiju MP et al 2010, Vipul 
M Khakhkhar et al 2012, Archana Sharma et al 2012, Abolfazl Gholipour et 
al 2014 and ModiDhara et al 2012.109,111,113,114,115 
  In the present study 74.28% ESBL producing Esch.coli and 43.47% ESBL 
producing Klebsiella shows resistance to cefepime. Sridar PN Rao et al 2014 
which correlate with present study.110 
 Sridar PN Rao et al 2014 documented significantly more numbers of ESBL-
Klebsiella  were resistant to cefepime than ESBL-Esch.coli, but the present 
study ESBL Esch.coli shows 74.28% and ESBL Klebsiella shows 43.47%.110 
 In the present study, all ESBL producers were uniformly resistant to 
ceftriaxone, ceftazidime and cefotaxime Esch.coli shows 70% and Klebsiella 
shows 46%. This data correlate with Sridar PN Rao et al 2014.110 
 Pitout JDD et al 2008 documented Co-resistance to amino glycosides is 
common in ESBL-producers, which does not correlates with present study. 
Present study shows 50 – 65% sensitivity to gentamicin and 75 – 90% to 
amikacin.2 
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 bla-CTX-M is the predominant gene found in the present study which is 
show a relationship with the studies done previously by Ensor et al 2006, and 
sirdar PN Rao 20014.106,110 
 In this study among the 58 ESBL producers Esch.coli 35 60.3% is the 
predominant ESBL producer and in Klebsiella 23 (30.7%) were ESL 
producers which correlates with most of the previous studies.30,81,106,107,108,116. 
 This study has some limitations. ESBLs are reported worldwide among 
different bacterial species; including Enterobacteriaceae and non-
fermentative Gram-negative bacteria such as Pseudomonas and 
Acinetobacter species. This study assessed ESBL only with 50 isolates of 
Esch.coli and 50 isolates of Klebsiella which are the common isolates in our 
Institute. 
 The small sample size may limit also the power of the study to recognize 
other resistant genes such as AmpC, Carbapenemase and other ESBL-
producers. 
 Needs further study with more number of samples and detection of other 
genes will ensure better understanding of ESL producers in the clinical 
samples in our Institution. 
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SUMMARY 
 A total of 100 isolates (50 Esch.coli and 50 Klebsiella) were isolated from 
various clinical samples were studied for ESBL production. In these isolates 
ESBL was detected by two steps as per CLSI 2010 guideline: Screening by 
resistant to 3rd Gen. Cephalosporins and Combination disk diffusion using 
ceftazidim and cefotaxime alone and with clavulanic acid. By phenotypic 
method, 35/50 (70%) of Esch.coli and 23/50(46%) were ESBL producers. It 
shows that Esch.coli has high prevalence than Klebsiella. 
 When the ESBL producers subjected to antibiotic sensitivity testing they 
were observed that all the 58 isolates were resistant to 3rd Gen. 
Cephalosporins such as cefotaxime, ceftriaxone and ceftazidime. At the same 
time it was found the isolates were resistant to Cefoxitin and Ciprofloxacin. 
 More than 70% of ESBL producers were sensitive to Amikacin and 
Imipenem, it shows that these drugs continue to be effective against ESBL 
producers.  
 With PCR technique, bla-TEM, bla-SHV, bla-CTX genes were detected 
among 58 isolates 35 Esch.coli and 23 Klebsiella which was confirmed as 
ESBL producers phenotypicaly.  
 Bla-CTX-M was the most common gene among Esch.coli and Klebsiella. 
 Other two genes bla-TEM and bla-SHV was detected in more number of 
Esch.coli than Klebsiella.  
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Flow chart 3: Summary 
 
Total n=100 
  
Esch.coli n=50 Klebsiella n=50 
  
ESBL screening ESBL screening  
    
Esch.coli+ve 
35 (70%) 
Esch.coli-ve 
15 (30%) 
 
Klebsiella+ve 
23 (46%) 
Klebsiella-ve 
27(54%) 
 
 
Phenotypical confirmation 
  
Esch.coli 35(60.3%) Klebsiella 23 (30.7%) 
  
Genotypical Confirmaton 
  
Esch.coli 35 (60.3%) Klebsiella 23 (30.7%) 
      
blaTEM 
26 
(74.28%) 
blaSHV 
21 
(60%) 
blaCTX-M 
29 
(82.85%) 
bla TEM 
15 
(65.21%) 
bla SHV 
12 
(52.17%) 
blaCTX 
19 
(82.60%) 
  
bla-TEM+bla-SHV=12 (34.28%) 
bla-SHV+bla-CTX=15(42.85%) 
bla-TEM+bla-CTX=20(57.1%) 
bla-TEM+bla-SHV+bla-
CTX=6(17.1%) 
bla-TEM+bla-SHV=4(17.39%) 
bla-SHV+bla-CTX=18(34.78%) 
bla-TEM+bla-CTX=11(47.82%) 
 
 
 
 
 
 
 
  
Conclusion 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
 
84 
 
CONCLUSION  
 The prevalence rate of ESBL producing Esch.coli was significantly 
higher than Klebsiella isolates in our Institution. 
 2nd and 3rd Generation cephalosporins and ciprofloxacin shows high 
resistance.  
 More than 70% of isolates shows high sensitivity to Amikacin and 
Imipenem. 
 CTX-M gene was detected in more number of Esch.coli and Klebsiella. 
 Antimicrobial policy making and strict adherence in the need of the day 
can prevent drug resistance. 
 Epidemiological studies of β-lactamases in each Institute and genetic 
environment of the clinical isolates would be useful to prevent 
bacteriological drug resistance. 
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PROFORMA 
Sree Mookambika Institute of Medical Science, Kulasekharam 
DEPARTMENT OF MICROILOGY 
Study title:  
        ”Extented spectrum beta lactamases screening in Escherichia coli and 
Klebsiella isolates and confirmation by molecular method”  
Serial Number : 
Name : 
Age/Sex : 
Hospital Number : 
Ward No : 
Sample type : 
Date of collection : 
Time of collection : 
Sample receiving time : 
Anti-biotic usage : Yes/No 
If yes details : 
 
Serial 
Number 
Name of the 
isolate 
 
Frequency 
Percentage 
ESBL +ve ESBL -ve 
1 E.coli   
2 Klebsiella   
 
Serial 
Number 
Antibiotics Resistance 
(%) 
Name of the organism 
 
E.coli Klebsiella 
    
 
  
 
 
 
 
CONSENT FORM 
PART 1 OF 2 
INFORMATION FOR PATICIPANTS OF THE STUDY 
Dear Participants, 
 
         We welcome you and thank you for your keen interest in participating 
in this research is being carried out. This form will provide you all the 
relevant details of this research. It will explain the nature, the purpose, the 
benefits, the risk, the discomforts, the precautions and the information about 
how this project will be carried out. It is important that you read and 
understand the contents of the form carefully. This form may contain certain 
scientific terms and hence, if you have any doubts or if you want more 
information, you are free to ask the study personnel or the contact person 
mentioned below before you give your consent and also at any time during 
the entire course of the project. 
 
Study title:  
        ”Extented spectrum beta lactamases screening in Escherichia coli and 
Klebsiella isolates and confirmation by molecular method”  
Name of the Principal Investigator: Dr.J.Jasmine Gnana SuthA 
Post Graduate Student 
Deportment of Microbiology  
SMIMS, Kulasekharam 
 
Name of the Guide Dr.N.Palaniappan , M.D 
Professor 
Deportment of Microbiology  
SMIMS, Kulasekharam 
 
Name of the Co-Guide Dr.P.Indu, M.D 
Professor 
Deportment of Microbiology  
SMIMS, Kulasekharam 
 
Institute:  Sree Mookambika Institute of Medical Science (SMIMS),   
                Kulasekharam, Kanyakumari District, Tamilnadu 
  
 
 
 
 
Background information:  
                 The phenotypical test for identification of ESBL based on disk-diffusion 
test is the most common strategy used in microbiology laboratories in India. 
However, this method has serious limitations, as additional resistance mechanisms 
can cause divergence in the results. Only few studies in India investigated the 
genotypic origin of ESBL, so there is little knowledge on the epidemiological 
aspects of the prevalence of these enzymes employing a phenotypic detection 
procedure based on the combined disk method and a genotypic method based on the 
detection of blaSHV gene using the polymerase chain reaction (PCR)[3,5,6]. 
Aims and Objectives: 
 To evaluate the prevalence of ESBL producing E.coli and Klebsiella in the 
clinical isolates at Sree Mookambika Institute of Medical Sciences, 
Kulasekaram. 
 To study the present status of antibiotic resistance in E.coli and Klebsiella. 
 To conform the phenotypically resistant E.coli and Klebsiella to genotypes.  
Scientific justification of the study: 
            The incidence of Extended Spectrum Beta Lactamase (ESBL) producing 
strains among clinical isolates (Klebsiella species and Escherichia coli) has been 
steadily increasing over the past years. ESBL producing organisms pose a major 
problem for clinical therapeutics. Identifying organisms that are ESBL producers 
  
 
 
 
 
are a major challenge for the clinical microbiology laboratory [7]. An attempt to study 
ESBL production and multidrug resistance in clinical isolates of Klebsiella and 
E.coli in Sree Mookambika Institute of Medical Sciences, Kulasekaram, 
Kanykumari district. 
Procedure for the study: 
             The samples will process and isolates will be identify by standard laboratory 
methods. Antibiotic susceptibility testing will done on Muller Hinton agar by Kirby 
Bauer’s disk diffusion method as per CLSI guidelines. A genotypic method based 
on the detection of blaSHV gene using the polymerase chain reaction (PCR) [9, 10].  
Expected risks for the study:  
          While collecting blood sample for testing there can be mild pain and bleeding 
in the site and during pus collection mild tissue injury and bleeding occurs very 
rarely, and its will be managed easily.   
Expected benefits of research for the participants: 
      This study can help the institution to make a new antibiotic regime which can 
be ofhelp for better cure. 
Maintenance of Confidentiality:  
          All information for study purpose only. We will not disclosed with others. 
Why have I been chosen to be this study? 
         The incidence of Extended Spectrum Beta Lactamase (ESBL) producing 
strains has been steadily increasing over the past years. ESBL producing organisms 
  
 
 
 
 
pose a major problem for clinical therapeutics. To study the present status of 
antibiotic resistance and to prevent ESBL producing E.coli and Klebsiella at Sree 
Mookambika Institute of Medical Sciences, Kulasekaram. 
1. How many people will be in the study?  NA 
2. Agreement of Compensation to the participant (In case of a study 
related injury):NA 
3. Anticipated prorated payment, if any, to the Participant(s), of the study: 
NA 
4. Can I withdraw from the study at any time during the study period? NA 
5. If there is any new findings/information, would I be informed?  NA 
6. Expected duration of the Participant’s participation in the study: NA 
7. Any other pertinent information: NA 
8. Whom do I Contact for further information? 
For any study related queries, you are free to contact: 
                         Dr. J.Jasmine Gnana Sutha 
                          Post graduate, Department of Microbiology 
                         Sree Mookambika Institute of Medical Sciences,  
                         Kulasekharam, Kanyakumari-629161. 
                         Mobile number: 9487662907, 
                         E-mail: sudhajas@yahoo.com 
Place: Kulasekaram 
Date:                                                         signature of the Principal Investigator  
  
 
 
 
 
CONSENT FORM  
PART 2 OF 2 
PARTICIPANTS CONSENT FORM 
             The details of the study have been explained to me in writing and the details 
have been fully explained to me. I am aware that the results of the study may not be 
directly beneficial to me but will help in the advancement of medical sciences. I 
confirm that I have understood the study and had the opportunity to ask questions. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. I agree not to restrict the use 
of any data or results that arise from this study provided such a use only for scientific 
purpose(s). I have been give an information sheet giving details of the study. I fully 
consent to participate in the study titled “Extended Spectrum Beta lactamases 
screening in Escherichia coli and Klebsiella isolates and confirmation by 
molecular method”. 
 
Name of the participant:                                            Address of the participant: 
 
Contact of the Participant:  
 
Serial no/Reference no: 
 
                                                      Signature/Thumb impression of the participant  
 
                                                              Witnesses: 
            Date:                                                          1. 
            Place:                                                         2. 
  
 
 
 
 
Xg;Gjy; gbtk; 
ghfk; 1 y; 2 
Ma;Tf;Fcl;gLj;jg;gLgtu;fSf;fhdmwpTiufs; 
 
md;ghdez;gu;fNs> 
cq;fSld; Ma;Tfis Nkw;nfhs;tjw;F ePq;fs; nfhLj;j Mu;tj;jpw;Fk; 
xj;Jiog;Gf;Fk; jq;fis tuNtw;W ed;wpapid njuptpj;J nfhs;fpNwd;. ,e;j 
gbg;gpd; Kf;fpakhd rhuhk;rq;fs; fPNo nfhLf;fg;gl;Ls;sJ. ,jpy; 
nfhLf;fg;gl;Ls;s xt;nthU thf;fpaq;fSk; kpfTk; Kf;fpakhd xd;whFk;. 
,jpy; VNjDk; re;Njfq;fs; ,Ug;gpd; ePq;fs; fPo;fz;l egu;fis njhlu;G 
nfhs;syhk;. 
 
1. topelj;Jgtu; ; :    kU.[h];kpd; QhdRjh 
Kjy; Mz;LKJepiyEz;Zapupay; 
gpupT. 
= %fhk;gpfhkUj;Jtfy;Yhup 
kUj;Jtkid. FyNrfuk;. 
 
2. topfhl;b   : kU.N.godpag;gd; 
 
3. ,iztopfhl;b  : kU.P.,e;Jkjp. 
 
4. fy;tpepWtdk;  : = %fhk;gpfhkUj;Jtfy;Yhup 
kUj;JtkidFyNrfuk;. 
 
5. jiyg;G   : Extended Spectrum Beta Lactamases         
                                                                screening in Esherichia coli and Klebsiella        
                                                                 isolates and confirmation by   molecular method. 
6. mbg;giltptuq;fs;   :   
 
,e;jpahtpy; nghJthf Ez;Zapupay; Ma;T $lj;jpy; ESBL  apd; 
Kf;fpakhd gupNrhjid Disk-Diffusion test. Mdhy; ,e;j 
Ma;TNkw;nfhs;tjw;F gpuj;Nafkhd tiuKiwfs; kw;Wk; tpjpKiwfs; 
  
 
 
 
 
cs;sJ. NkYk; ,e;j Nrhjidfs; Nkw;nfhs;Sk; NghJ mjd; KbTfs; 
vg;NghJk; xNukhjpupahf fpilg;gjpy;iy. ESBL  apd; Ma;tpidFwpj;J 
,e;jpahtpy; NghJkhd tpopg;Gzu;T ,y;iy. mjdhy; ,e;jpahtpy; ,e;j 
Ma;T ,d;Dk; tsu;r;rp ngwtpy;iy. Poly merase chain reaction (PCR) 
Kiwia gad;gLj;jp blaSHV apid fz;Lgpbf;f Phenotypic detection 
procedure cjTfpwJ. 
 
7. gad;ghLfs; : 
a) = %fhk;gpfh kUj;Jt fy;Yhup kUj;Jtkidapy; E.coli Klebsilla d; 
ESBL cw;gj;jp nra;Ak; jd;ikapid Muha;jy;. 
b) E.coli Klebsillatpy; Neha; vjpu;g;Gjd;ik Fiwtjw;fhd fhuzk; 
fz;lwpjy;. 
c) Phenotypically resistanceE.coli Klebsilla-tpd; Genotype apid 
fz;lwpjy; 
 
8. mwptpay; tpjpKiwfs; 
 
   ESBL cw;gj;jp nra;Ak; mZf;fs; fle;j tUlj;ij tplTk; mjpfupj;J 
,e;j Ez;Zapu;fis fz;lwpe;J Ma;T Nkw;nfhs;tJ kUj;JtJiwf;F 
rthyhd tp\akhFk;. = %fhk;gpfh kUj;Jt fy;Yhup kUj;Jtkidapy; 
E.coli  Klebsillad; ESBL cw;gj;jp nra;Ak; jd;ikapid gw;wpa Ma;Tfs; 
Nkw;nfhs;tJ ekf;F rhjfkhFk;. ,J Clinical Isolate d; E.coli  Klebsillaapy; 
ESBL cjtpAld; mjw;Fupa rupahd antibiotics gad;gLj;Jtjw;fhd Ma;T 
nra;jpl toptFf;Fk;. = %fhk;gpfh kUj;Jt fy;Yhup kUj;Jtkidapy; 
ESBL ia cw;gj;jp nra;Ak; mZf;fs; mjpfupj;JtUk; #oypy; Antibiotic 
resistancy kw;Wk; mjid jLf;Fk;; Kiwfs; gw;wpfz;lwpjy;. 
 
9. gbg;GKiw: 
,jw;Fkhjpupfs; (sample) Nrfupf;fg;gl;L mjw;Nfw;w Ma;tpd; %yk; 
fz;lwpjy;.  
 
  
 
 
 
 
10. ,e;j Ma;Tfspdhy; Vw;gLk; fbdk; : Ma;tpw;f;fhf ,uj;jk;, rPo; 
vLf;Fifapy; rpWtyp my;yJ ,uj;jfrpT Vw;g;gl tha;g;G cs;sJ. 
Mdhy; ,J vspjpy; rup nra;jpLk; xd;Nw. 
 
11. ,e;j Ma;Tf;fhd Nehf;fk;  : kUj;Jtu;fSf;F Gjpa Mz;bgahl;bf; 
Kiw mikg;gjw;f;Fk; mjd; %yk; gadhspfSf;F jukhd 
kUj;Jtk; fpilj;jpl ,e;j Ma;T cjtpLk;. 
12. ,ufrpak; fhj;jy; : jfty;fs; Ma;Tf;fhf kl;LNk gad;glj;jgLfpd;wJ. 
 
13. ,g;gbg;ig gbg;gjd; Nehf;fk; 
ESBL cw;gj;jpnra;Ak; mZf;fs; fle;j tUlj;ij tplTk; 
mjpfupj;J ,e;j Ez;Zapu;fis fzlwpe;J Ma;T Nkw;nfhs;tJ 
kUj;JtJiwf;F rthyhdtp\akhFk;. = %fhk;gpfh kUj;Jtfy;Yhup 
kUj;Jtkidapy; E.coli  Klebsillad; ESBL cw;gj;jp nra;Ak; jd;ikapid 
gw;wpa Ma;Tfs; Nkw;nfhs;tJ ekf;FrhjfkhFk;. ,J Clinical Isolate d; 
E.coli  Klebsillaapy; ESBLcjtpAld; mjw;Fupa rupahd antibiotics 
gad;gLj;Jtjw;fhd Ma;T nra;jpl toptFf;Fk; 
 
kU.[h];kpd; QhdRjh. 
KJepiyEz;Zapupay; gpupT. 
%fhk;gpfhkUj;Jtfy;YhupkUj;Jtkid 
FyNrfuk;.Fkupkhtl;lk; 629161 
nkhigy; 9487662907 
e-mail:sudhajas@yahoo.com 
     
ehs;:                       Kjd;ikMa;thsupd; ifnahg;gk; 
,lk;: 
 
     Ma;Tf;Fcl;gLj;jg;gLgtupd; ifnahg;gk; 
 
  
 
 
 
 
Xg;Gjy; gbtk; 
ghfk; 2 y; 2 
Ma;Tf;F cl;gLj;jg;gLgtu;fSf;fhd Xg;Gjy; gbtk; 
 
     ,e;j Ma;Tf;fhd tpsf;fk; ehd; GupAk;gb vdf;F nrhy;yg;gl;Ls;sJ. ,e;j 
Ma;T Neubahf vdf;F gadspf;fhJ Mdhy; kUj;Jt gbg;GfSf;F cjtpahf 
,Uf;Fk; vd;gij njupe;J nfhz;Nld;. Ma;T rk;ke;jkhd Nfs;tpfis vd;dplk; 
Nfl;f ehd; rk;kjpf;fpNwd;. Ma;Tf;F ehd; cl;gLj;jg;gLtJ yhg Nehf;fkw;wJ 
vd;Wk; ,t;tha;tpypUe;J ve;NeuKk; tpLtpf;fg;glyhk; vd;gijAk; mwpe;Js;Nsd;. 
vd;id cl;gLj;jp fpilf;Fk; Ma;T KbTfis kUj;Jt gbg;Gf;fSf;fhf 
gad;gLj;jpnfhs;s jil nra;akhl;Nld; vd;W cWjpaspf;fpNwd;. vdf;F Ma;T 
gw;wpa tpsf;fTiu toq;fg;gl;Ls;sJ. ehd; “Extended Spectrum Beta Lactamases 
screening in Esherichia coli and Klebsiella isolates and confirmation by   molecular 
method” vd;w kUj;Jt Ma;Tf;F cl;gLj;jg;gl kd;g;G+u;tkhf rk;kjpf;fpNwd;.  
 
 
Serial no./ Reference No. : 
. 
Ma;Tf;Fcl;gLj;jg;gLgtupd; ngau;:      Ma;Tf;Fcl;gLj;jg;gLgtupd; Kftup: 
 
 
 
Ma;Tf;Fcl;gLj;jg;gLgtupd; njhlu;Gvz;:  
 
 
Ma;Tf;Fcl;gLj;jg;gLgtupd; ifnahg;gk; 
 
 
rhl;rpfs;:  
         1. 
         2. 
ehs;: 
,lk;:  
